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The current study examined the diverse ways individuals with co-occurring Posttraumatic Stress 
Disorder and Substance Use Disorders (PTSD-SUD) attend treatment. The study was a 
secondary analysis of a randomized controlled trial for PTSD-SUD (Ruglass et al., 2017), in 
which participants meeting criteria for both PTSD and SUD (N=82) were randomized to either 
Concurrent Treatment of PTSD and SUD using Prolonged Exposure (COPE: n=39) or Relapse 
Prevention Therapy (RPT: n=43).  Latent class growth analysis (Muthén & Muthén, 2000) 
revealed three distinct classes of attendance as the model of best fit. Diagnostic, but not 
demographic, variables were significantly associated with treatment attendance patterns. 
Namely, the number of trauma exposures and the presence of co-occurring Major Depressive 
Disorder (MDD) were associated with attendance patterns.  Titrators (n=26) were more likely to 
have multiple traumas compared to those subjects who were droppers (n=26), the participants 
who attended the fewest overall sessions. Titrators (n=26) were more likely to have current 
MDD than completers (n=30). In the initial treatment phase (baseline – session 4), self-report of 
PTSD symptom severity decreased more quickly for titrators (n=26) than for completers 
(n=30). There were no significant differences within the initial treatment phase in terms of 





predictive of attendance class in this sample of those with PTSD-SUD. Finally, the distribution 
of attendance class patterns did not vary across treatment types, COPE or RPT. Understanding 
the heterogeneity of those with PTSD-SUD including the relationship between variables that 
describe this diversity and attendance irregularities may improve treatment engagement and 
effectiveness on an individual and programmatic level, as well as facilitate appropriate resource 
allocation. Future efforts to clarify the relationship between baseline patient characteristics, 
treatment attendance patterns, rates of improvement and psychotherapy outcomes may offer 
support for treatment delivery models of increased flexibility and individualization.  
Keywords: posttraumatic stress disorder, substance use disorder, dropout, attrition, 
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CHAPTER 1: INTRODUCTION 
Study Rationale 
Retrospective studies indicate that for a large majority of cases of co-occurring PTSD-
SUD, PTSD develops prior to SUD. Data from prospective studies has demonstrated that PTSD 
does contribute to increased risk for the development of SUD (Stewart & Conrod, 2003). Many 
individuals with PTSD report consuming substances in efforts to gain short-term relief from the 
distress of trauma-related symptoms. The use of substances to avoid the painfulness of trauma 
sequelae lends support to the self-medication hypothesis of addiction (Jacobsen, Southwick, & 
Kosten, 2001; McCauley, Killeen, Gros, Brady, & Back, 2012), a cyclical process reinforced by 
withdrawal symptoms (Brady, McCauley, and Back, 2014) and the development of cravings in 
response to trauma cues (Coffey et al., 2002). Literature from the trauma and addiction fields 
detail treatment engagement and compliance as primary concerns interfering with recovery. 
Carroll (1997) asserts that among those meeting criteria for alcohol and substance use disorders, 
“rates of treatment dropout range from 25 to 90 percent” (p.6). Souza, Spates, & Rankin (2012) 
note that, “as levels of avoidance increase, the likelihood of an individual seeking, complying 
with, and completing treatment for PTSD decrease significantly” (p.103) meaning that those 
most in need of intervention are also those less likely to receive it (Pineles, Mostoufi, Ready, 
Street & Griffin, 2011). For those with dual diagnoses, as substances leave the body, trauma 
symptoms return, oftentimes with greater intensity. Many treatment settings for those meeting 
criteria for PTSD, SUD, or the dual-diagnosis enforce strict requirements for patient attendance 
given wait lists and overburdened mental health resources for those with limited financial means. 
While concordant with some theoretical and clinical approaches, this policy when universally 
applied to a population with PTSD-SUD may not only lack a sufficient scientific basis, but may 





dissociation, enactment, or (un)conscious awareness of the felt-need to modulate the emotional 
impact of disclosure and treatment participation. Flexible and compassionate responses to 
missed-sessions in the context of ongoing clinical engagement may be of greater benefit than 
termination (Bernard, 1994). For those with PTSD-SUD, the longer the duration of PTSD care 
(with attendance at 2 or more sessions per month), the greater the likelihood of substance use 
remission (Ouimette, Moos, and Brown, 2003), a finding that suggests that while treatment 
attendance matters, “good enough” dosing may be sufficient for the achievement of clinically 
significant improvement. Emerging evidence from both the trauma-specific treatment literature 
(Powers, Halpern, Ferenschak, Gillihan, & Foa, 2010) and the co-occurring trauma-addiction 
treatment literature (Hien et al., 2012) reveals that for some patients attending more treatment 
sessions within a given time frame does not always result in improved outcomes. Indeed, a 
subset of this population may exhibit greater positive effects when allowed some flexibility with 
attendance as a mechanism for the regulation of treatment dosage.  
For a diagnosis of PTSD in non-substance-using populations, the American 
Psychological Association (APA) identifies exposure-based therapy as highly effective treatment 
with strong research support (DeAngelis, 2008; Foa, Keane, Friedman, & Cohen, 2010). 
Prolonged exposure (PE) involves repeated recounting of the traumatic events including 
thoughts, emotions, and physiological sensations associated with the memories. A meta-analysis 
of 13 randomized controlled trials of prolonged exposure found it to be a “highly effective 
treatment for PTSD that confers lasting benefits across a wide range of outcomes” (Powers et al., 
2010, p.639).  Though PE is considered an evidenced-based practice that represents the “gold 
standard“ in clinical care for trauma-exposed populations, some research has linked this 





increased symptom severity (e.g. suicidal ideation, depression, panic attacks) for some patients 
(Pitman, 2002). Thus while prolonged exposure has the capacity to facilitate significant symptom 
relief, tolerability has been a concern prompting research and debate. 
Prolonged exposure therapy was initially conceptualized in case studies as potentially 
inappropriate for those with concurrent substance dependence because of cognitive impairment 
or increased risk of relapse, but given that most individuals with substance disorders were 
excluded from studies on PE, evidence may have been insufficient to make this claim (Souza et 
al., 2012; Mills, Teesson, & Back, 2012).  Instead of rejecting the use of exposure-based 
techniques and their potential long-term benefits, experts in the field of substance abuse 
treatment have begun to consider how to use these methods for patients with co-occurring PTSD-
SUD safely and effectively.  
Given the particular retention difficulties inherent to work with a population diagnosed 
with PTSD-SUD (Najavits, 2015) and the anticipated or experienced stress associated with 
symptomatology and treatment, an examination of the unique contributions of type of treatment 
with and without Prolonged Exposure provides critical data to understand the ways patients 
attend in a dynamic, interactive environment. Exploring attendance patterns, patient-
characteristics at baseline (e.g. years of education, number of trauma exposures, additional co-
occurring psychopathology, primary substance of use), and diagnostic and symptoms changes 
post-treatment helps identify clinically relevant subsets of those seeking relief from PTSD-SUD, 
a process itself facilitative of tailored interventions maximizing opportunities for successful 







Study AimsIn the primary analyses of efficacy studies, the attention paid to treatment 
“completers” sometimes overshadows the experiences of those who attended irregularly or 
dropped out prior to the fulfillment of a specified definition of sufficient treatment. 
Consequently, those individuals who did not pursue further participation following 
randomization or attended an insufficient number of sessions for full analysis in particular 
studies are less visible. Previous research contributes to the conceptualization of a sufficient 
treatment dose, but this literature does not always integrate the sometimes-divergent perspectives 
of clinicians, researchers, and participants. Differences in criteria for treatment completion across 
studies make direct comparisons and resultant interpretations challenging (Tuerk et al., 2011, 
401). 
Authors may note limitations related to whose data is central in their analysis and 
hypothesize whether there may be any unaccounted for differences between those who 
completed treatment and those who did not. Researchers may be able to articulate whether any 
differences on studied variables reached significance, but if this is the case, it is unlikely that 
they will be the point of emphasis. Moreover, patients with premature termination (also variably 
defined) from treatment have missing data, which makes it statistically and clinically challenging 
to determine the meaning of missing sessions. Titrators, participants who attend regularly 
initially and then less so as treatment progresses, (Hien et al., 2012) provided data that 
contributed to our understanding of clinical processes at play. When statistical means present a 
global picture, the obfuscation of clinically significant variance across subjects with different 
attendance patterns may be lost. Knowing that a one-size-fits-all approach fits some, efficacy and 
effectiveness studies may be able to capture and communicate the essential information 





Co-occurring PTSD-SUD diagnoses are associated with a wide range of negative clinical 
outcomes including: high substance use severity (Najavits, 2007); high rates of self-destructive 
or high-risk behaviors (Najavits, 2007); elevated risk for treatment dropout (Ford, Hawke, 
Alessi, Ledgerwood, & Petry, 2007; Brady, Dansky, Back, Foa, & Carroll, 2001); and relapse 
following SUD treatment (Hien, Nunes, Levin, & Fraser, 2000; Najavits, 2007). 
Concurrent treatment of PTSD and substance use disorders using prolonged exposure 
(COPE) is an integrated treatment that is a synthesis of Relapse Prevention (cognitive behavioral 
therapy for addictive disorders) and Prolonged Exposure (for PTSD) (Back et al., 2012).  In its 
first randomized control trial (RCT), Mills and colleagues (2012) found that the combined use of 
COPE plus usual treatment (e.g. detoxification, maintenance therapies) compared with usual 
treatment alone resulted in improvement in PTSD severity without an increase in the severity of 
substance dependence. 
This research builds on a number of case and pilot studies indicating that prolonged 
exposure may be beneficial among participants with co-occurring substance use disorders. 
Coffey, Staslewicz, Hughes, and Brimo (2006) compared six PE sessions plus group and 
individual SUD treatment with a comparison group receiving 6 imagery-based relaxation 
sessions in addition to group and individual SUD treatment. The imaginal exposure group 
experienced a reduction in PTSD symptoms and alcohol cravings, while there were no 
significant changes in trauma symptoms for those in the relaxation group (Coffey et al., 2006). 
These findings suggested that adding exposure-based PTSD treatment to SUD treatment might 
have some benefit in reducing alcohol related craving symptoms in those with PTSD-SUD in 
addition to positive effects on trauma symptoms (Coffey et al., 2006). Support for COPE’s 





AUD, which demonstrated that an Integrative Therapy (IT) group with 1 or more sessions of 
Prolonged Exposure had superior outcomes on measures of PTSD symptom severity (blind, 
clinician-administered assessment) when compared to the IT group without PE (Sannibale et al., 
2013). At five months post-treatment, the superiority of outcomes remained (Sannibale et. al, 
2013).  
The larger, randomized NIDA-funded clinical trial (N=110) from which the present study 
derives compared the efficacy of Concurrent Treatment of PTSD and Substance Dependence 
(COPE) and Relapse Prevention Therapy (RPT) to an active monitoring control group (AMCG) 
for those with co-occurring PTSD-SUD (Ruglass et al., 2017). COPE and RPT demonstrated 
significant superiority in reducing PTSD symptom severity when compared to AMCG. Both 
active treatments were also superior to AMCG in reducing the days of use for the primary 
substance. Among those participants with full PTSD, COPE showed greater decreases in trauma 
symptomatology relative to RPT (COPE-RPT=-21.32, 95% CI-42.37 to -0.28, p=.047). In 
contrast, there were no significant differences between COPE and RPT on trauma symptoms 
among participants with sub-threshold PTSD and SUD (p=0.92) (Ruglass et al., 2017, p.6). 
Among participants who met criteria for full PTSD as compared to subthreshold PTSD, COPE 
may have a greater effect on PTSD symptoms when compared to a SUD-only treatment (p.1). 
The use of prolonged exposure resulted in a decline in PTSD symptom severity with no 
worsening of substance use (Ruglass et al., 2017). Of relevance to the current study, the primary 
analysis determined that the mean number of sessions attended by participants randomized did 
not differ significantly between treatments (COPE: mean = 6.08, SD = 4.75 vs. RPT: mean = 





The present study (N=82) conducted latent class analysis to examine the attendance 
pattern of treatment-seeking participants with PTSD-SUD assigned to receive 12 sessions of 
Relapse Prevention Therapy or COPE.  In doing so, the present study built upon the variable-
centered approach of the primary outcomes paper (Ruglass et al., 2017) by contributing a person-
centered approach. Following the identification of distinct attendance patterns among 
participants, an analysis of the relationship between treatment type and attendance patterns 
contributes evidence regarding whether integrated therapy using prolonged exposure with a 
substance-dependent population differentially affects treatment dropout or titration vis-à-vis 
cognitive behavioral therapy without prolonged exposure (RPT). A further analysis of baseline 
participant characteristics and their association with attendance patterns provides an opportunity 
for greater understanding of which treatments may work most effectively for which individuals 
with PTSD-SUD. The present study examined the relationship between attendance patterns and 





CHAPTER 2: LITERATURE REVIEW 
Overview 
The present review examines the literature related to psychotherapy treatment attendance 
including research on associations between attrition and diagnostic variables related to trauma, 
substance use, symptom severity, and co-occurring psychopathology. Lastly, a summary of the 
literature on treatment for co-occurring PTSD-SUD with particular attention to treatment 
engagement via attendance has been included.   
Treatment Attendance: Conceptual Framework and Related Methodologies 
Varied definitions and determinations for dropout, attrition, treatment failure, and early or 
premature termination represent multiple attendance-related constructs using similar terminology 
and methods of operationalization (Barrett et al., 2008). Definitions of treatment completion and 
completers have also differed, though perhaps with a less chaotic evolution. Attendance 
irregularities use overlapping criteria to describe participants’ behavior including: missing the 
first or last session (Hatchett et al., 2002); missing consecutive sessions; failing to attend a 
predetermined number of total sessions, discontinuing treatment against clinical advice (Pulford, 
Adams, & Sheridan, 2009) or failing to achieve a predetermined ratio of sessions attended vis-à-
vis sessions offered. Attendance irregularities as a term itself is a misnomer given the common 
occurrence of dropout, attrition, and premature termination, but will be used to encapsulate the 
diverse ways patients may be considered to not “complete” treatment, described most frequently 
as attending a specified and predetermined number of sessions considered to be sufficient by 
clinical researchers and/or insurance company representatives. Dropout has been used to refer to 
anyone who has ended treatment early, though this may include reference to study participants 
who drop out after 0 or 1 session or who may have attended on average 16 sessions (López-Goñi, 





definitions and draws attention to the cultural and treatment context in which particular terms are 
used. Dropout as a term may also include patients who received referrals to pursue treatment 
elsewhere due to clinic or research exclusion criteria or exhibited behavior in the midst of 
treatment that required a higher level of care. Occasionally early dropout increases the specificity 
of the term, as it may with attrition, a word that generally appears to denote the occurrence of a 
patient-determined ending spanning the course of treatment, variably defined. The term 
premature termination or early termination appears most consistently linked to the experience of 
a patient not informing a clinician about his or her plan to stop attending sessions or the 
experience of a patient and a clinician disagreeing about whether termination is indicated. This 
term, like dropout, also may include patients who have attended few or numerous sessions.  
For clarity’s sake, this paper will use the terms dropout, attrition and attendance 
irregularities, but rarely early or premature termination. Specific parameters will be included 
when possible without becoming unwieldy. In addition, the terms treatment titration and 
titrators will also occur within this paper. Treatment titration refers to the patient-initiated 
process of beginning treatment with a high level of consistency and then, following the initial 
treatment phase, attending subsequent sessions with less overall consistency (Hien et al., 2012). 
Titrators differ from completers in that they miss more sessions than completers who 
demonstrate a more stable rate of overall attendance (Hien et al., 2012).   
Sometimes we are able to learn something about those participants who miss sessions. 
However, a lack of consensus regarding attendance-related terminology (Matthieu & Ivanoff, 
2006) coupled with insufficient reporting and transparency in measurement of these variables 
within RCTs and other clinical research contexts pose challenges to clinicians, researchers, and 





(2012) illustrated the difficulties of making direct comparisons of psychotherapy research given 
differences in construct definition. In their study of attrition, Warnick et al. (2012) found that 
predictors of attrition varied markedly based on which of three distinct definitions was utilized—
the statistical relationships between predictors and attrition differed based on whether attrition 
was based on 1) clinician judgment, 2) a specified dose, or 3) a missed last appointment.  
Clinicians and consumers may view treatments disparately given the potential for 
incongruence in the goals of symptom relief or other measure of change. Zayfert and colleagues 
(2005) suggested that definitions of attrition and dropout used within clinical settings vis-à-vis 
research settings may be especially divergent with treatment completion in clinical settings 
linked to positive outcomes and a mutually agreed on termination by clinician and patient. 
Discrepancies between dropout rates in RCTs and studies that are more naturalistic have been 
widely noted in the literature (Najavits, 2015). Missing sessions may occur for a multiplicity of 
reasons. However, those who attend treatment irregularly due to the effects of the therapeutic 
intervention or a discrepancy between the expectation and the actual course of treatment are 
particularly problematic (Foa, Keane, & Friedman, 2000).  
 In psychotherapy outcomes research, attrition contributes to lost data and greater 
ambiguity in the analysis of treatment outcomes through threats to both internal validity (through 
an alteration of group composition) and external validity (whenever those who leave treatment 
differ from those who complete it on any dimension other than attendance status) (Harris, 1998). 
Statistical exclusion or inclusion of dropouts from analyses has consequences of positioning 
therapies in a more or less favorable light than may be warranted (Matthieu & Ivanoff, 2006). 
Selection bias due to dropout is an occurrence that does not have an adequate correction 





necessary and important, will not replace the data that is lost to dropout. While the Consolidated 
Standards of Reporting Trials provides guidance on reporting clearly defined attendance data for 
all enrolled participants as part of an intention to treat approach (Altman, 1996), there is 
variability in implementation of these recommendations. Complete-case analysis, imputation-
based procedures and model-based procedures are the three primary methods available for 
statistically handling missing data (Little & Rubin, 2002). Each of these statistical approaches 
has associated problems (Matthieu & Ivanoff, 2006; Deluchi, 1994). Simplicity of a given 
statistical approach may lead to its implementation when another methodology may be more 
appropriate.  
        Literature suggests that treatment dosage does have variable impact on symptom 
reduction and reoccurrence of symptoms. The ways patients attend treatment sessions (e.g. 
lateness, missing sessions) have a direct impact on the type, quality, quantity and relational 
context of clinical interventions to which they are exposed. How clinicians and treatment 
delivery systems view non-attendance or attendance irregularity is likely to further influence 
client attendance. If non-attendance is viewed as a response to the dominance of a particular self-
state, one that may be dissociated from other parts of a patient’s experience and that may be 
unconsciously resisting overwhelming affect –whether partially related to the experience of a 
previous intervention or as (un)conscious anticipation of what may be opened up in treatment—
this is likely to impact how clinicians communicate with those who have not shown up.  Thus the 
professional contexts in which clinicians are treating patients additionally affects responsiveness 
to patients’ missed sessions.  
Recent research suggests that a minimum of eleven to thirteen evidence-based sessions 





(Hansen, Lambert & Forman, 2002, Lambert, 2007). Though this finding may obscure variability 
based on individual, therapist, diagnostic, and intervention differences, it does highlight the 
importance of considering how patients attend therapy and promotes the consideration of what 
constitutes an adequate dose for whom.  
 The Good Enough Level Model or GEL model (Barkham et al., 1996) suggests that the 
level of treatment duration and the level of patient improvement serve a co-regulating function so 
that patients tend to leave treatment when a patient’s improvement has reached a good enough 
level. The GEL level may evolve over the course of treatment, likely influenced by a variety of 
factors including satisfaction level and symptomatology. Expectation of dose (i.e. number of 
therapy sessions) appears to have some influence on rate of symptom improvement (Barkham et 
al., 1996) though responsiveness, including adjustments to treatment length and intervention type 
may improve the therapeutic relationship.  Barkham et al. (2006) studied the GEL model via an 
application of reliable and clinically significant improvement (RCSI) (Jacobson & Traux, 1991), 
a construct that requires 1) reliable pre-post improvement and 2) clinically significant change 
frequently operationalized as a shift from a clinical to a non-clinical presentation.  The large 
individual differences in achieving reliable and clinically significant improvement (Barkham et 
al., 2006) suggest that imposing standardized limitations on session number, a common practice 
among insurance companies and treatment clinics for resource-related purposes, may be 
inappropriate. The negative acceleration of the aggregate dose-effect curve for psychotherapy 
does not mean the average individual dose-effect curves for psychotherapy would also show 
negative acceleration. Session twelve is not inherently less potent than session three; on an 
aggregate curve, easier to treat patients will have responded by session twelve and ended 





time points on the dose-effect curve different aggregations of patients are represented (Kopta et 
al., 1994). Consequently, the aggregate will yield a negatively accelerating curve even though 
there may be some patients or some presenting problems with linear dose-effect responses.   
 Various efforts can be made to increase retention and reduce attendance irregularities: 
including phone reminders (Gariti et al. 1995)), motivational interventions (Dench & Bennett, 
2000), role induction (Zwick and Attkisson 1985), positive reinforcement (Petry, Martin, 
Cooney, & Kranzler, 2000) though these have had mixed results (Ogrodniczuk, Joyce, & Piper, 
2005). Consequently, some suggest focusing efforts on treatment-fit including increased 
availability to shorter term interventions that may maximize the likelihood that a patient receives 
the optimal intervention suited to likely attendance (Pulford, Adams, & Sheridan, 2009; López-
Goñi et al., 2011). This approach, particularly if involving patients in the decision-making 
process, may support patient self-efficacy and facilitate a strong initial therapeutic alliance (Reis 
& Brown, 2006; Barrett et al., 2008), a factor implicated in treatment completion and positive 
treatment outcomes. Patients report greater rates of staff, program-related, and logistical issues 
for dropout than do clinicians (Ball, Carroll, Canning-Ball, & Rounsaville, 2006).  These 
differences in perspective could be explained in part by attribution theory (Heider, 1958), which 
suggests that individuals are more likely to attribute negative personal experiences to external 
factors while attributing the negative experiences of others to internal causes. Utilizing patients’ 
preferences, goals, and logistical realities to inform treatment planning in its initial stages in a 
respectful manner may be effective in maximizing intervention hours and increasing openness to 
the range of psychotherapeutic approaches in the future. Some patients may be able to reduce or 
discontinue treatment prior to “completion” with no ill effects, though this may not be the case 





of research linking attendance patterns to diagnostic and clinical variability at baseline as well as 
to treatment outcomes.   
Treatment Attendance and Demographic Data 
There are several patient-specific variables studied in relation to psychotherapy 
attendance and dropout; however, only a few have demonstrated a more consistent association. 
Though entry into mental health or substance-specific treatment settings may vary, gender is not 
necessarily a predictor of retention, completion, or outcome once treatment has been initiated 
(Greenfield et al., 2007). Key demographic variables including the experience of economic 
disadvantage, racial/ethnic minority status, and limited education have demonstrable links to 
early disengagement from psychological treatment (Barrett et al., 2008). Defife et al. (2010) 
found “individuals with greater barriers to care such as those who are younger, ethnic minorities, 
living farther away from treatment settings, poorly insured, less educated or of lower 
socioeconomic status have greater no-show rates” (p. 414). Younger or emerging adults (below 
age 30) have higher rates of dropout than mature adults (Edlund, 2002; Olfson et al., 2002). Low 
socioeconomic status (SES) is the strongest predictor of attendance among studied demographic 
factors (Beckham, 1992). Epidemiological survey research further corroborated the finding that 
low SES has been fairly constant in its association with psychotherapy dropout rates (Edlund et 
al., 2002) with moderate effect sizes between .23 and .37 (Wierzbicki & Pekarik, 1993; Edlund 
et al., 2002). The impact of SES, however, appears to be particularly significant in the initiation 
period of psychological treatment. A meta-analysis that differentiated between early dropout and 
later dropout (after session four) revealed the association between low SES and dropout was 
more closely linked with early dropout as opposed to later attrition (Barrett et al., 2008). While 





of factors than attrition later in treatment (Barrett et al., 2008), this level of analysis is absent 
from much of the psychotherapy process literature.  
Treatment Attendance and Traumatic Exposure 
 Evidence suggests that the experiences and symptoms associated with PTSD are 
associated with higher rates of treatment attendance irregularities (Najavits, 2015; 
Schottenbauer, Glass, Arnkoff, Tendick & Gray, 2008).  The emotion regulation deficits central 
to the disorder in conjunction with the difficulties inherent in creating and maintaining trust for 
individuals who have experienced interpersonal traumas necessitate an intentional therapeutic 
approach. Thus, the current standard of practice for post-traumatic therapy is a three-phase 
model focusing on: 1) safety and stabilization 2) memory reconstruction and emotional 
processing and 3) integrated learning and adaptive living (Courtois & Ford, 2009, p. 49-52). 
Trauma-specific treatments vary in the emphasis placed on one or more of the aforementioned-
phases, a characteristic linked to the specific theoretical underpinnings of the intervention and 
evidence related to symptom reduction, recovery, and integration. Those individuals with severe 
PTSD or complex trauma are thus particularly vulnerable to difficulties with treatment 
engagement and titrating session participation may serve as a means to regulate anxiety and other 
forms of distress (Hien et al., 2012).    
Evidence suggests that high PTSD symptom severity is associated with treatment 
attrition. In a retrospective chart-review of veterans receiving one of two EBPs for PTSD 
(Prolonged Exposure or Cognitive Processing Therapy), a history of psychiatric inpatient 
hospitalization was associated with decreased likelihood of treatment completion (Mott et al., 
2014). Farrugia and colleagues (2011) found that individuals with PTSD-SUD who had 





PTSD-SUD whose trauma exposures occurred only in adulthood. As a group, those with 
childhood trauma exposure exhibit greater clinical severity in multiple ways related to both 
substance use and trauma. With regard to substances, those with PTSD-SUD and childhood 
trauma exposure have higher scores on measures of substance dependence; higher numbers of 
drug treatment episodes, higher numbers of drug classes used over the life course, have an earlier 
age of first use and of first intoxication. This population of individuals with PTSD-SUD and 
childhood trauma is also associated with more extensive lifetime exposure to trauma, more 
diversity in type of trauma exposure, and experiences longer duration of PTSD symptoms 
(Farrugia et al., 2011). Individuals with child trauma exposure and childhood sexual abuse in 
particular are vulnerable to re-traumatization as adults (Farrugia et al., 2011, p.322). 
Retraumatization is associated with more complex PTSD symptom presentation in addition to 
co-occurring anxiety disorders of various types, depression, and self-harm (Farrugia et al., 2011, 
p.322). 
Those exposed to trauma as children who later develop PTSD –SUD often have 
experienced or witnessed interpersonal violence within the context of their closest relationships. 
Early, repeated trauma exposure can lead to neurobiological changes in emotional sensitivity 
levels (Siegal, 1999) with increased vulnerability to subsequent emotional challenges and a 
lowered threshold for dysregulation (Hien, Litt, Cohen, Miele, & Campbell, 2009). Childhood 
maltreatment is associated with HPA axis dysregulation as an adult (Koenen, 2010), a finding 
which details the pervasive impact of trauma on multiple physiological regulatory processes –
including those related to the capacity to modulate mood and emotion, factors in turn related to 





Those with Complex PTSD resulting from chronic or long-term exposure to trauma 
(Herman, 1997) have relatively high rates of attending treatment inconsistently. This may occur 
within the context of ongoing communication with providers whether by phone contact or by 
disappearing and resurfacing. Variable treatment engagement is reflective of the disturbed 
attachment patterns often seen in those with Complex-PTSD (Hien, Litt, Cohen, & Miele, 2004; 
Hien et al., 2010; Herman, 1997).  Avoidance is a central element of PTSD, with the avoidance 
of trauma-related thoughts, feelings, and situations not infrequently transferred to the avoidance 
of therapy itself.  
Dropout rates from randomized controlled trials of CBT for PTSD range dramatically 
from 0% (Glynn et al., 1999; Zayfert et al., 2005) to 43% (Power et al., 2002). Dropout from 
CBT for PTSD has been associated with baseline anxiety (Taylore, Fedoroff & Koch, 1999; van 
Minnen, Arntz, & Keijsers, 2002), depression, (Bryant, Moulds, Guthrie, Dang, & Nixon, 2003), 
guilt, an additional psychiatric diagnosis, and PTSD symptom severity (Taylore, Fedoroff & 
Koch, 1999). Within a clinical treatment setting using conservative criteria for completion, 
Zayfert et al. (2005) found baseline PTSD avoidance symptoms to be associated with lower rates 
of treatment completion of CBT for PTSD.  
Despite significant allocation of resources by the Department of Veterans Affairs to offer 
evidence-based treatments for PTSD (Shiner et al., 2013), specifically Prolonged Exposure and 
Cognitive Processing Therapy, 25-30% of veterans who begin the ten- to fifteen-week 
intervention do not complete the ‘prescribed’ treatment course with eight sessions denoted as the 
minimum dose (Hernandez-Tejada et al., 2014). A majority of those veterans meeting criteria for 
full PTSD (DSM IV) at baseline who received in-person therapy (as opposed to telemedicine) 





While it is unlikely that this set of responders was wholly asymptomatic, the finding does 
dovetail with a meta-analysis of 13 Prolonged Exposure studies that revealed “no significant 
relationship between effect size and dose (number of sessions)” (Powers et al., 2010, p.640) to 
suggest that the parameters of a “good enough” recovery may elude generalizability.  
Treatment Attendance and Substance Misuse 
 The findings regarding the relationship between substance misuse and attendance 
irregularities are mixed. Early age of substance use has been associated with higher dropout rates 
(Agosti, Nunes & Ocepeck-Welikson, 1996) as well as poly-drug use (Fishman, Reynolds, and 
Riedel, 1999; Wickizer et al., 1994). Active substance use negatively influenced regular 
appointment attendance in a clinical setting (DeFife at al, 2010). Individuals in treatment for 
substance misuse have high rates of early dropout, with rates as high as 50% in the first month 
(Stark, 1992). 
 Some evidence suggests that the ways patients attend treatment have a relationship to the 
primary substance of misuse. In a Spanish study, Lopez-Goni et al. (2011) found that a 
significantly higher proportion of those who left a 12-month treatment program early initiated 
treatment for alcohol misuse vis-à-vis cocaine misuse, while other researchers have shown 
higher dropout rates among cocaine users (McKellar, Kelly, Harris, et al., 2006; McKellar, 
Harris, Moos, 2006). Divergent expectations and definitions of attendance and treatment 
completion may explain some of these differences as may the good enough level (GEL) model.    
 Among others, Flores (2001) conceptualized substance misuse as maladaptive coping to 
facilitate internal self-regulation in lieu of interpersonal relationships. This conceptualization 
suggested that individuals with substance misuse who also have anxious attachment styles or 





 While some individuals are ambivalent regarding reducing or abstaining from alcohol or 
substances particularly in the absence of less adaptive coping skills, co-occurring difficulties, 
some of which patients may recognize as driving or related to use, often inspire far less 
ambivalence. Still, many with co-occurring disorders who also have substance misuse have 
challenges accessing treatment for other problems if alcohol or substance use exceeds parameters 
set by clinics that deem themselves ill-suited for work with heavy substance users. Many patients 
with dual diagnoses encounter limitations in their access to the full range of available treatments. 
Stigma and the cloak of invisibility it casts on co-occurring problems, greater accessibility of 
abstinence-only self-help programs, and structural separation from other behavioral health 
provision lead many patients toward a path of addressing substance issues first in isolation from 
PTSD and other co-occurring disorders which many are attempting to minimize via self-
medication. The need for substance detoxification and rehabilitation facilities remains; however, 
it is understandable that treatment dropout will be higher for clients who in wanting to address 
co-occurring depression, anxiety, or posttraumatic symptoms receive the message that their 
treatment goals and priorities are of secondary importance. The potential for less attuned clinical 
experience is elevated when the roots and co-occurring complexities of an individual’s 
diagnostic picture remain out of focus. Less choice in the clinical context related to an insistence 
on sequential treatment with substances addressed first may in turn contribute to weak initial 
alliance, more negativistic attitudes toward treatment, reduced confidence in treatment-efficacy, 
increased hopelessness regards to the intractability of clients’ own problems. The negatively 







Treatment Attendance and Co-occurring Psychopathology 
              Beyond demographic, trauma and substance-related predictors, psychiatric severity has 
demonstrated links with missed psychotherapy appointment rates, particularly for those on either 
end of the symptom spectrum (DeFife at al., 2010, p. 414). High symptom severity at initial 
presentation to treatment is predictive of premature termination (Derisley & Reynolds, 2000, p. 
371), however treatment completers are also often considered to have greater impairment than 
treatment non-completers (Barkham et al., 1996). 
There is evidence that patients’ diagnostic symptoms and classifications may be a partial 
determinant of the ways in which they attend psychotherapy. While patients in varied treatment 
settings tend to have co-occurring mental disorders, the evidence base for specific 
psychotherapies has been based largely on participants with single disorders given delineated 
exclusion criteria maximizing internal validity (Miranda, Azocar, and Burnam, 2010, p. 205).        
There are high rates of co-occurring depression, anxiety and borderline personality 
disorder among studies using samples of individuals with PTSD-SUD (Farrugia et al., 2014), a 
finding that holds true despite the exclusion of those who are actively self-harming or suicidal 
when assessed. Evidence suggests that when PTSD-SUD occurs in conjunction with other 
disorders, it is more difficult to treat—particularly when the additional disorders implicate high 
levels of negative affect. Major Depressive Disorder as well as Persistent Depressive Disorder 
can be characterized—at least in part—by prolonged, intense and frequent experiences of high 
negative affect, with a high symptom correlation between self-report and clinician-report 
(Farrugia et al., 2014; Owens, 2014, Gross, 1998). Norman, Tate, Wilkins, Cummins & Brown 
(2010) found that the severity of depression symptoms among those who also met criteria for 





not meet criteria for PTSD-SUD. Relatedly, comorbid PTSD-Depression was also found to be 
more difficult to treat when compared to the treatment of a single disorder in two veteran studies 
(Campbell et al., 2007; Walter, Barnes, & Chard, 2012; Owens 2014). More severe depression 
was negatively associated with retention in depression treatment (Bech et al., 2003) and among 
those with polysubstance use and MDD, treatment retention has been shown to be problematic 
(Schaub et al., 2011).  
In addition to the association between high negative affect and higher levels of substance 
misuse (frequency and quantities consumed), high negative affect has been shown to interfere 
with cognitive processes that are facilitative of adaptive coping (e.g. effective decision-making) 
(Henderson, 2011), factors which in turn are associated with psychotherapy attendance 
irregularities including missed sessions.  
Using an urban primary care patient population, Mohr et al. (2006) found a significant 
relationship between depression and increased perception of emotional barriers to psychotherapy 
(e.g. concerns about what others would think, discomfort talking about personal issues, concerns 
about being seen while emotional) whereas practical barriers (e.g. proximity to psychotherapy, 
time constraints, transportation difficulties) were not consistently associated with depression. Co-
occurring depressive symptoms or diagnoses were associated with higher rates of both treatment 
refusal and dropout among outpatients with anxiety disorders (Isaakidis & Andrews, 2004).  
Severity of psychiatric and medical symptoms was found to be related to retention rates 
among women in residential treatment for substance dependence (N=203), in which those with 
greater number and severity of problems had lower retention rates (Greenfield et al., 2007). 
However, in a residential treatment center for substance dependence with participants exhibiting 





rates were higher for those with higher depression scores at baseline when implementing 
treatment as usual or a condensed present-centered treatment for co-occurring PTSD-SUD 
(Seeking Safety).  
Treatments for Co-occurring PTSD and SUD 
Historically, providers recommended sequential care –with SUD treated first and PTSD 
addressed subsequently following the achievement of abstinence. An empirically supported shift 
towards a harm reduction approach in the treatment of substance use disorders has occurred 
contemporaneously to movement in clinical PTSD research from efficacy trials on interventions 
designed to address simple PTSD to those focused on both efficacy and effectiveness for those 
with complex PTSD and co-occurring disorders.Growing evidence indicates the need for 
concurrent treatment as patients with comorbid PTSD and SUDs have unique clinical concerns 
that require an approach that is distinct from PTSD patients without SUDs. For example, when 
compared with either disorder alone, co-occurring PTSD-SUD is associated with higher rates of 
additional comorbidities (Jacobsen et al., 2001); higher symptom severity, lower psychosocial 
functioning, worse physical health, elevated risk for suicidality, and negative treatment outcomes 
(Capone, Eaton, McGrath, McGovern, 2014). Unique clinical concerns for those with PTSD-
SUD also include comparatively worse outcomes in substance use treatments and elevated risk 
for substance-related relapses (Glasner-Edwards et al., 2013; Read, Brown, & Kahler, 2004; 
Resko & Mendoza, 2012; Kacskurkin, et al., 2016). Though those with PTSD-SUD are difficult 
to treat, there is evidence that has demonstrated dual-focused treatment to be superior to single-
focused treatment (Abueg & Fairbank, 1991; Ouimette, Moos & Finney, 2003; Cocozza et al., 
2005). Failing to address PTSD in patients with PTSD-SUD may contribute to more entrenched 





those with alcohol dependence and other co-occurring Axis 1 psychiatric diagnoses (Foa, Yusko, 
and McLean, 2013).  
In response to the need for integrated evidence-based treatments that are both effective 
and cost efficient, new therapies were developed including present-focused interventions, such as 
Seeking Safety (Najavits, 2002) and Integrated Cognitive Behavioral Therapy (ICBT) For PTSD 
and Substance Use (McGovern, Lambert-Harris, Alterman, Xie, Meier, 2011) and those focused 
on the in-depth processing of past trauma. Concurrent treatment of PTSD and substance use 
disorders using Prolonged Exposure (COPE) (Back et al., 2012) and Cognitive Processing 
Therapy (Resick & Schnicke (1993) are methods which directly address experiences of past 
trauma. Like the trauma-specific treatments with a more narrow focus, interventions for co-
occurring PTSD-SUD often emphasize a single phase of the aforementioned three phases of 
trauma treatment delineated by Herman (1997). Seeking Safety (Navajits, 2002), for example, 
which addresses issues of safe coping and stabilization via attention to interpersonal and 
emotional regulation, privileges this first phase and stage of treatment. In contrast, the COPE 
treatment moves from a focus on safety and stabilization in early sessions (1-4) to a central focus 
on phase two of trauma treatment – the emotional processing of traumatic memories. 
The challenge of developing a treatment for patients with SUD and PTSD centers on the 
primary tasks of bolstering skills to initiate and maintain sobriety, while also using effective 
trauma techniques that will promote rather than interfere with recovery from substances. Hien et 
al. (2009) acknowledges the inherent difficulties working within the therapeutic window with 
individuals with PTSD-SUD given the diagnostic centrality of avoidance and emotional 
dysregulation; errors in the pacing of treatment for this population may result in clients using 





           The field lacks consensus regarding what constitutes the best treatment for those with 
PTSD and co-occurring SUD (Najavits and Hien, 2013; Berenz & Coffey, 2012). While certain 
treatments are the gold standard for either PTSD or Substance Use Disorders, there is 
considerable variation in the ways that clinicians are working with individuals with one of these 
disorders and even greater treatment diversity for those with a dual diagnosis. Some 
psychotherapy research scholars have challenged the validity of gold standard claims– arguing 
that it is rare for one treatment to outperform another non-waitlist intervention, with successful 
treatment hinging on more universal therapeutic elements. Though both sides of this debate have 
amassed considerable research, the argument denoting the value of common therapeutic elements 
does not itself provide sufficient evidence to discredit the demonstration of the success of gold 
standard therapeutic approaches for some patients in specified contexts. Prolonged Exposure for 
PTSD and Relapse Prevention Therapy for Substance Use Disorder have received the gold 
standard designation, making both therapies worthy of consideration in the formulation of 
integrated treatment for PTSD-SUD given utilization outcomes for the targeted single disordered 
populations. Exposure-based methods including Prolonged Exposure has been shown to decrease 
other traumatic stress-related difficulties including anger, guilt, and depression (Hernandex-
Tejada et al., 2014) emotional factors that are also implicated in substance misuse.  
A recent study of U.S. veterans found that among those who completed at least eight 
sessions of PE treatment, the “proportion of patients screening positive for PTSD on the PTSD 
Checklist decreased from 87.6% to 46.2%” (Eftekhari et al., 2013, p.410). However, assignment 
to treatment type was not random and approximately one quarter of participants who initially 
agreed to PE treatment dropped out prematurely (Morris, 2015). Study design, reporting 





information related to those dropping out prematurely or attending treatment with greater 
irregularity. Though premature dropout is a clinical occurrence across treatment types, the extent 
to which dropout or treatment titration occurs more within Prolonged Exposure treatments vis-à-
vis other therapies is of clinical import. Najavits (2015) as the author of a present-centered 
approach to addressing PTSD-SUD, advocated for the designation of gold standard to be 
assigned to those with strong performance in both RCTs and in the “real-world” with its wider 
array of settings, programs and patients.  
Early research on Prolonged Exposure with co-morbid PTSD-SUD used case studies of 
individuals with PTSD and SUD (varied types) treated with prolonged exposure, and 
demonstrated mixed results (Brady, Dansky et al., 2001). Souza et al. (2012) published a case 
study of an individual with co-occurring PTSD, Alcohol Use Disorder and Cannabis Use 
Disorder with sustained positive outcomes at six months post-treatment, while other examples 
presented contradictory findings.  
Building upon case analyses, Brady and colleagues (2001) found that participants with 
PTSD and cocaine dependence who received exposure therapy (n=39) and attended at least ten 
of the sixteen scheduled sessions (n=15) demonstrated reduction in PTSD symptoms across all 
diagnostic symptom clusters (e.g. re-experiencing, increased arousal) and cocaine use, changes 
sustained at six months post-treatment. Characteristics between treatment completers (ranging 
from ten to sixteen sessions attended) and non-completers differed on two baseline variables: 
completers reported fewer avoidance symptoms on a self-report measure (Impact of Events 
Scale) though not on a clinician-administered assessment (CAPS) and were more educated 





Concurrent treatment of PTSD and substance use disorders using prolonged exposure 
(COPE) is an integrated treatment that is a synthesis of Relapse Prevention (cognitive behavioral 
therapy for addictive disorders) and Prolonged Exposure (for PTSD) (Back et al., 2012). In its 
first randomized control trial, Mills and colleagues (2012) found that the combined use of COPE 
plus usual treatment (e.g. detoxification, maintenance therapies) compared with usual treatment 
alone resulted in improvement in PTSD severity without an increase in the severity of substance 
dependence. Cocaine-dependence was the primary substance addressed in the original COPE 
manual though subsequent alterations, including the one used in the current study, address 
problem-behaviors associated with diverse drug classes. Ruglass et al. (2017) compared COPE to 
RPT and an active monitoring control group, and found both COPE and RPT to have a 
significant impact on PTSD symptom severity and days of substance use. While COPE and RPT 
did not have significant differences in PTSD severity outcomes in the intent-to-treat sample, 
those participants with full PTSD (vs. subthreshold PTSD) showed greater reduction in PTSD 
symptom severity when receiving COPE as compared to RPT. The use of PE did not worsen 
substance use among those with PTSD-SUD.  
Treatment Attendance and Co-occurring PTSD-SUD 
 A review of fourteen studies including 1,506 participants with PTSD-SUD found that 
simultaneous or integrated treatment of trauma and SUD was more effective (small effect) than 
treatment as usual; SUD only or trauma-only treatment, despite lower rates of treatment 
completion with use of trauma-specific treatment (Roberts, Roberts, Jones and Bisson, 2016).  
Although this is not exclusive to this particular population, the absence or varied nature 
of reporting treatment attendance data among those with PTSD-SUD makes it challenging to 





literature with this dually diagnosed population, Najavits and Hien (2013) name a primary 
limitation of their analysis as the inability to address treatment attendance. Attendance was 
“defined inconsistently in studies, sometimes with no clear denominator (how many sessions 
were available to clients), sometimes reported only for those attending a certain amount of the 
study treatment, and sometimes not reported” (Najavits & Hien, 2013, p. 434). In a meta-analysis 
of therapies for co-occurring PTSD-SUD, Roberts et al. (2016) also reported multiple studies 
with methodological problems with “high” or “unclear” risk of bias related to detection and 
attrition. If those assigned to a particular treatment drop out early due to the perceived or 
experienced nature of the assigned intervention (whether positive or negative), failure to include 
this data potentially misrepresents treatment viability or the need to differentiate therapeutic 
services based on patient characteristics. Treatments with the best empirical support may not be 
as widely effective as sometimes portrayed, even if successful with a significant subset of an 
impacted population.   
Alcohol and benzodiazepine use have predicted dropout and influenced treatment 
outcomes in patients receiving Prolonged Exposure for PTSD (van Minnen et al., 2002). Daily 
benzodiazepine use was associated with reduced likelihood of dropout from PE; however, this 
therapy was less effective for this population subset, perhaps due to hypothesized interference 
with fear activation during exposure, the mechanism believed to drive effective habituation (van 
Minnen et al., 2002; Foa & Kozak, 1986). 
Hien and colleagues (2012) examined attendance patterns and treatment outcomes for 
women involved in 12-sessions of two different types of rolling group treatments: Seeking 
Safety and Women’s Health Education. This randomized clinical treatment study included 





(N=353).  The Seeking Safety treatment (Najavits, 2002) is a short-term manualized therapy, 
which uses cognitive behavioral strategies to reduce the negative impact of trauma exposure and 
active substance use in either the group or individual modality (Hien et al., 2012, p. 33).  For this 
study, only the group modality was utilized. Women’s Health Education (Miller et al., 1998) is a 
psychoeducational intervention that focuses on knowledge of the physical body, human sexual 
behavior, pregnancy and childbirth, nutrition, and general health. Hien et al. (2012) found three 
different latent attendance patterns of significance across this multi-site trial. Completers 
attended at least 80% of sessions (~48% of the sample); while titrators had high rates of 
attendance through the seventh session and more sporadic attendance thereafter with session 
attendance probability falling between 50-80% (28% of the sample). The third subset of the 
sample, denoted droppers, tended to discontinue treatment by the fourth session (24% of the 
sample). For those in Seeking Safety, there was no evidence suggesting that completers derived 
additional benefits from a greater dose of therapy in comparison to the titrators with respect to 
substance use, a finding that remained over the course of a 12-month follow-up period (Hien et 
al., 2012, p.37).  
Case Illustration: Handling the PTSD-SUD Attendance Data 
           An RCT (N=165) conducted by Foa and colleagues (2013) examined patients with co-
occurring alcohol dependence and PTSD who were randomly assigned to one of four groups: 
prolonged exposure therapy plus naltrexone (100mg/d); prolonged exposure therapy plus pill 
placebo; supportive counseling plus naltrexone (100mg/day) or supportive counseling plus 
placebo.  Figure 1 of the primary outcomes paper detailed the flow of participants through the 
trial (p.490) with a 32.1% dropout rate (53 participants across all 4 groups) prior to the end of the 





were reported as follows: 26% dropout for supportive counseling+placebo; 31% for supportive 
counseling+naltrexone; 35% for prolonged exposure+naltrexone; and 38% for prolonged 
exposure+placebo. Twelve participants from the study were removed for adverse effects 
described as non- study related. Foa and colleagues (2013) include the level of detail regarding 
participants’ attendance and dropout data that meets (if not exceeds) the standard of care and 
transparency required for publication in peer-reviewed journals with significant impact factors 
(JAMA). In addition, statistical analyses occurred with the intent-to-treat sample meaning data 
for all participants was included. Replacement or imputation of data was not necessary given the 
use of hierarchical linear and nonlinear modeling. The mean and standard deviation for the two 
groups receiving prolonged exposure were included in the paper; however, these statistics were 
not reported for supportive counseling+placebo and supportive counseling plus naltrexone. There 
is a somewhat ambiguous definition provided for dropout, which while less troublesome when 
viewed in isolation given the statistical methods employed, is more problematic for cross-study 
comparison.  While a research article in a separate but cited journal provides details regarding 
the study design and methodology, it is unclear which sessions focused on psychoeducation or 
consolidation of skills, and which utilized in vivo or imaginal exposure (Foa et al., 2013).  
               If as a researcher, clinician or informed consumer, it were easy to examine the session 
numbers when key interventional elements are introduced vis-à-vis session attendance data for 
each treatment phase, important clinical research data regarding tolerability, avoidance, symptom 
relief and recovery might be highlighted in ways more conducive for future study.  Reporting 
every detail lacks feasibility, however, greater clarity with regard to the timing of participants’ 
departure from treatment or the numbers attending the first imaginal exposure session vis-à-vis 





regarding attendance for this and other studies might include: the relative proportion of early vs. 
later dropouts, the extent to which some dropouts may be better understood as titrators, and 
whether those who did dropout or titrate treatment were experiencing relief or evidence of non-
responsiveness.  
Statement of Hypotheses 
Specifically, the current study examined whether there are distinct attendance patterns in a 
sample of participants diagnosed with PTSD-SUD and whether there were differences in 
attendance between the two active randomly assigned treatments, COPE and RPT. The study 
aimed to add to a body of literature interested in the ways in which attendance patterns may be 
associated with particular change trajectories as well as client/clinician individual differences 
given the implications of this knowledge is greater individualization and effectiveness in 
treatment planning for those impacted by PTSD-SUD. The current study aims to elaborate upon 
the primary findings of Ruglass et al. (2017) in addition to those of Hien et al. (2012), the latter 
of which modeled differential treatment effects which showed that the benefits of a trauma-
focused treatment were most evident among a class of titrators (defined as attending between 50-
80% of offered sessions). The current analysis presented an opportunity to examine whether an 
integrated treatment that incorporates prolonged exposure (COPE) will be associated with 
attendance/outcome relationships similar or distinct from the group-implementation of a present-
centered Seeking Safety treatment studied by Hien and colleagues (2012). Thus, the current 
study expands on the variable-centered primary outcome adherence analysis by using a person-
centered approach in efforts to clarify whether more flexibility with regard to treatment 







In a sample of individuals with PTSD-SUD, multiple patterns of treatment attendance 
were expected.  Variations in the ways individuals with PTSD-SUD attended treatment sessions 
occur in naturalistic studies as well as in RCTs (Najavits, 2015). Besides highlighting subsets 
who drop out of treatment within the first few sessions (Foa et al., 2013), a number of studies 
have shown that some individuals with PTSD-SUD remain connected to treatment providers 
after initial engagement, but in a manner that involves decreased regularity in attending 
subsequent prescribed treatment sessions (Hien et al., 2012).  Meaningful sub-groupings have 
been noted with this population (Greenfeld et al., 2007; Greene et al., 2017) with clinical 
treatment studies noting at least two (Foa et al., 2013) if not three (Hien et al., 2012) sub-
groupings based on the ways therapy sessions were attended.  
Hypothesis 1A 
An association among attendance patterns and socioeconomic status as well as a number 
of diagnostic and clinical variables pertaining to the complexity and chronicity of symptoms 
were expected. Specifically, attendance patterns were expected to be associated: with severity of 
substance use (DeFife at al., 2010), type of substance use (van Minnen et al., 2002), number of 
trauma exposures, childhood exposure to trauma (Herman, 1997), and the presence of additional 
co-occurring disorders characterized by emotional dysregulation, specifically Major Depressive 
Disorder (Ghee et al., 2009; DeViva, 2014).  
Hypothesis 1 B 
If multiple latent attendance classes among this sample of subjects with PTSD-SUD are 
identified, the distribution of attendance class membership across treatment type could provide 





completers were anticipated, given some association between high symptom severity or the 
presence of comorbidity with less receptivity to exposure therapy (Jaeger, Echiverri, Zoellner, 
Post, & Feeny, 2009). Some evidence that dropout from Prolonged Exposure typically occurs 
prior to the imaginal exposure suggested that greater numbers of droppers and titrators might be 
found among COPE recipients compared to RPT recipients (Schottenbauer, et al, 2008; Zayfert 
et al., 2005).  
Hypothesis 2 
The current study hypothesized that treatment attendance will have an effect on outcome 
measures of post-traumatic stress and substance use given the significant implications that 
problems with retention and dropout have for treatment outcomes (Hoge et al., 2014; Najavits, 
2015). An examination of attendance class membership on posttraumatic stress symptoms and 
substance use was planned.  
 
  
Figure 1. PTSD Symptoms in the Initial Treatment Phase  
BL = Baseline Assessment, MI=Motivational Interviewing session/Randomization S1= 





CHAPTER 3: METHOD 
Study Design 
 This study was a secondary analysis of a subset of the data from a NIDA funded clinical 
trial with a randomized, controlled, repeated measures design that assessed the efficacy of two 
active treatments, Concurrent Treatment of PTSD and Substance Dependence (COPE) and 
Relapse Prevention Therapy (RPT), to a delayed treatment control condition in treating 
individuals with substance dependence and PTSD. Eligible participants (See Sample) were 
randomly assigned to one of three groups: (1) COPE, (2) RPT, or (3) an Active Monitoring 
Control Group (AMCG). This clinical trial used repeated outcome measures at baselines; post-
treatment; and 1, 2, and 3 months post-treatment. Trained therapists with at least a Master’s 
degree administered the COPE and RPT interventions on an individual basis for twelve 90-
minute weekly sessions. RPT was administered in 90-minute sessions to eliminate the potential 
confounding factor of session length. Patients randomized to the AMCG condition participated 
in weekly self-assessments in addition to alcohol and drug tests monitored by administrative staff 
as opposed to a single designated clinician, as was the case for those randomized to RPT and 
COPE.  
 First, treatment trajectories were examined to see if there were distinct ways participants 
engaged with regards to attending sessions (e.g. early dropout, treatment titration, treatment 
completion). Subsequently, demographic and diagnostic subject-specific baseline characteristics 
were studied to determine whether they were predictive of attendance class membership. The 
study considered whether the number and nature of trauma exposures, the presence of a co-
occurring MDD diagnosis, and substance use severity predicted the ways subjects attended 
sessions. Next, the distribution of participants’ attendance class patterns across the two active 





rates for those randomized to a treatment involving prolonged exposure, a method of direct 
engagement with details of the trauma the subject continues to experience as most distressing. 
Lastly, the study was limited in its capacity to examine relationships between attendance pattern 
and treatment outcomes due to sample size.  
Procedure 
Sample 
Participants in this sample (N=82, 33% Female, 59.76% Black/African American) were 
men and women drawn from a larger study sample (N=110) of individuals with co-occurring 
PTSD-SUD located at The City College of New York’s Trauma and Addiction Project and 
assigned to COPE (N=39), RPT (N=43), or AMCG (N=28) (Ruglass et al., 2017). Those 
randomized to AMCG were not included in this secondary analysis due to methodological 
differences for recording session attendance for this group. AMCG participants had greater 
flexibility surrounding their clinical engagement, as the weekly commitment was not linked to a 
specific, individual therapist with limited availability, making any comparisons with active 
treatment groups invalid.  
Participants were eligible for treatment study inclusion if they met Diagnostic and 
Statistical Manual of Mental Disorders 4th ed. – text revision (DSM-IV-TR) (American 
Psychiatric Association, 2000) criteria for full or sub-threshold PTSD in the past 30 days as 
assessed by the Clinician-Administered PTSD Scale (CAPS). Participants with sub-threshold 
PTSD met Criterion B (re-experiencing symptoms) and either Criterion C (avoidance of trauma 
reminders) or Criterion D (hyperarousal) symptoms, but not both (Grubaugh et al., 2005). In a 
treatment-seeking sample, subthreshold PTSD is associated with social and work functioning 





Franklin, and Zimmerman, 2002). Other inclusion criteria included: being between the ages of 18 
and 65; being able to understand English; having some alcohol or illicit substance use within the 
past 30 days; and meeting DSM-IV-TR criteria for current or past substance dependence.  
Participants were excluded if they demonstrated: impaired mental cognition as evidenced 
by a score of 21 or less on the Mini-Mental Status Exam (Folstein, Folstein, & McHugh, 1975); 
significant risk of suicide or homicide within the previous 6 months as determined by the 
Psychiatric Research Interview for Substance and Mental Disorders (Hasin, Trautman, & 
Endicott, 1998); involvement in a relationship with active domestic violence; a history of 
schizophrenia-spectrum diagnosis or active psychosis, as clinically assessed by the Psychotic 
Screener of the Structured Clinical Interview for DSM Disorders (SCID); or a diagnosis of a 
bipolar spectrum disorder as assessed by the SCID. Additionally, participants already receiving 
trauma-specific treatment or those on antidepressants, mood stabilizing medications, or 
methadone-initiated or altered during the eight weeks prior to study participation were excluded 
from the study. Excluded participants received referrals for appropriate clinical services.  
Recruitment of participants began in September 2008 and ended in June of 2014. Patients 
were recruited from advertisements on Craigslist and in free local NYC newspapers as well as 
from local medical research centers. Interested participants (N=2,100) completed a brief screen 
assessment by phone, with those passing initial eligibility (N=992) scheduled for a more formal 
assessment. Of those who showed up for the baseline assessment (N=595), 212 did not meet 
inclusion criteria and 221 met exclusion criteria. 162 of the 595 baseline participants were 
determined to be eligible. 110 of the 162 eligible participants were randomized in a follow-up 
session that focused on treatment consent and a structured motivational interviewing session 





Concurrent Treatment of PTSD and Substance Dependence (COPE) intervention, Relapse 
Prevention Therapy (RPT), or a delayed treatment group. AMCG participants were re-assessed at 
the end of the twelve-week intervention period and if eligible received either concurrent 
treatment (COPE) or Relapse Prevention Therapy (RPT) at that time, or if they were no longer 
eligible for treatment were provided with more appropriate treatment referrals. All participants 
completed weekly assessments for substance use and PTSD symptoms in addition to the 
completion of a breathalyzer test and urine toxicology assessment.  Full assessments occurred 
after intervention for the COPE and RPT groups at one week, one month, two months, and three 
months afterward.  
Randomization 
Randomization was stratified by sex in addition to baseline symptom severity. Scores on 
the Addiction Severity Index-Lite and the Clinician-Administered PTSD Scale were used to 
classify symptom severity of substance/alcohol use and post-traumatic symptoms at baseline.  
Urn randomization procedures were subsequently utilized to balance these factors across groups. 
Research assessors were blind to group assignment. Participants consented to study involvement 
prior to notification of group assignment by a research assistant (Ruglass et al., 2017).   
Behavioral Interventions 
Concurrent Treatment of PTSD and Substance Used Disorders Using Prolonged 
Exposure (COPE). Concurrent treatment for PTSD and SUDs with Prolonged Exposure 
(COPE) was developed as an integrated psychotherapy that uses empirically validated treatment 
approaches (cognitive behavioral strategies and prolonged exposure techniques) to address both 
PTSD and SUDs simultaneously. COPE is a manualized 12-week intervention designed to 





patients receive psychoeducation related to (1) the underlying principles of cognitive and 
exposure-bases therapies and (2) to the interrelatedness of PTSD and substance use. Direct 
teaching of coping skills, relapse prevention techniques and cognitive restructuring are used to 
reduce the severity of patients’ substance use, whereas in-vivo and imaginal exposure techniques 
are used to diminish PTSD symptom severity via fear habituation processing (Back et al., 2014).  
The initial COPE sessions (1-3) focus on psychoeducation, goal-setting and cognitive 
behavioral strategies (e.g. connecting trauma and substance use; identifying triggers for 
substance use; developing a cravings plan; identifying thoughts linked to substance use; 
substance refusal skills and breathing retraining). In order to address avoidance behaviors and 
fear associated with traumatic memories, session four focuses on the development and 
subsequent use of an individualized in vivo hierarchy of safe yet avoided situations. The use of 
imaginal exposure begins in session five. In Vivo and Imaginal Exposures continues through 
session eleven. Participants have prolonged contact with feared situations until levels of 
subjective distress decrease significantly. Throughout the imaginal exposures, participants 
repeatedly provide a recounting of their most distressing traumatic memory in the present tense 
with particular emphasis on expressing thoughts, emotions, and physical sensations for 30-45 
minutes during the session. Participants listen to audio recordings of their retellings daily 
between sessions. Relapse prevention strategies, particularly those explicitly focused on the 
relationship between PTSD triggers and substance use, also are a part of each 90-minute session. 
Participants also record their progress in exposure work, substance use cravings and use of 
learned coping skills (Ruglass et al., 2017, p.3). The twelfth session focuses on skills review and 
consolidation in addition to termination. Participants had up to fourteen weeks for treatment 





             Relapse Prevention Therapy (RPT).  Relapse prevention therapy (RPT) is a widely 
used cognitive-behavioral approach developed to specifically address the occurrence of lapse or 
relapse episodes for individuals with addictive behaviors and to provide coping strategies useful 
in maintaining abstinence (Marlatt & Gordon, 1985; Marlatt, Parks, & Witkiewitz, 2002; Marlatt 
& Donovan, 2005). RPT involves supporting a client’s ability to identify and cope with high-risk 
situations. Through RPT, clients learned to implement self-control strategies as well as to 
develop lifestyles of greater balance with the aim to improve overall coping capacity and 
increase self-efficacy over time (Marlatt et al., 2002). The RP model does not consider (re)lapse 
as treatment failure, but as a complex process in which setbacks provide educative opportunities 
in a dynamic, multi-determined context (Hendershot, Witkiewitz, George, & Marlatt, 2011). 
Relapse Prevention has sustained main effects in diverse treatment settings (Witkiewitz & 
Marlatt, 2004) across all classes of substance use with positive outcomes in terms of both use 
reduction and psychosocial functioning (Carrol,1996).  
               The randomly assigned Relapse Prevention Therapy group had forty-three participants 
in this study who were randomized to receive twelve 90-minute sessions (to control for session 
length). The sessions did not explicitly target trauma or PTSD symptomatology, instead focusing 
on increasing self-efficacy skills for the prevention of relapse. The sessions incorporated 
psychoeducation, role-plays, and active problem-solving exercises, with supplementary at-home 
assignments. Participants had up to fourteen weeks for treatment completion.   
Measures 
Demographic Variables  
             Demographic and Treatment History Form (DEMO) is a structured 62-item social and 





not limited to: family history, age of onset of substance and/or psychiatric problems, history of 
hospitalizations, previous treatment, symptoms, and diagnoses (Hien & Zimberg, 1991). The 
measure was administered at baseline, immediately following the 12-week intervention, and at 1, 
2, and 3 months post-treatment.  
Attendance  
              An Attendance Log recorded the dates all participants attended individual treatment 
sessions and assessments. Active treatment sessions (COPE, RPT) were scheduled for 90 
minutes and videotaped. Session attendance ranged from 0 to 12 sessions.  
Trauma and Posttraumatic Symptoms 
Life Events Checklist (LEC). The Life Events Checklist (LEC) is a measure of exposure 
to potentially traumatic events that was used in conjunction with the Clinician-Administered 
PTSD Scale (CAPS) to facilitate a PTSD diagnosis (Gray, Litz, Hsu, & Lombardo, 2004). The 
LEC provides a snapshot of the types, timing, and frequency of trauma exposures that happened 
to, were witnessed by, or learned about by the respondent.  
Clinician-Administered PTSD Scale (CAPS). The CAPS is a structured, clinical interview 
for assessing the presence, frequency and intensity of core and associated symptoms of PTSD. 
The CAPS has standard prompts and “explicit, behaviorally-anchored rating scales” (Blake et al., 
1995, p. 75). The CAPS measures symptoms incorporated into the DSM-IV-TR PTSD diagnosis 
as well as associated symptoms, many of which have since been incorporated into the DSM-5 
diagnosis for PTSD. Impairments in social and occupational functioning, overall response 
validity and overall symptom severity were also determined.  Through re-assessment, the CAPS 
has the capacity to capture the degree of improvement since an earlier rating.  The CAPS has 





score (r= .87) and strong convergent validity with the Structured Clinical Interview for DSM-IV 
(SCID)–PTSD module (r = .83) (Foa & Tolin, 2000, p. 189).  The CAPS has excellent 
psychometric properties: test–retest reliabilities ranged from .77 to .96 for the three symptom 
clusters and from .90 to .98 for the 17-item core symptom scale (Blake et al., 1995).  
The Modified PTSD Symptom Scale Self-Report (MPSS-SR). The modified PSS-SR 
(Falsetti, Resick, Resnick, & Kilpatrick, 1992; Falsetti, Resnick, Resick, & Kilpatrick, 1993) 
measures frequency and severity ratings of PTSD and has been used in treatment and community 
samples. The modification of the PSS-SR is found to have good overall internal consistency and 
good concurrent validity with the SCID (Falsetti et al., 1992; Falsetti et al., 1993). Additionally, 
the scale was shown to be valid with a sample of participants with SUD; the measure had 89% 
predictive validity with clinician-administered diagnostic interviews (Coffey, Dansky, Falsetti, 
Saladin, & Brady, 1998).  The MPSS-SR has demonstrated high concurrent validity with the 
CAPS among similar co-morbid PTSD-SUD treatment samples (Ruglass, Lopez-Castro, Cheref, 
Papini, & Hien, 2014), suggesting its reliability as a tool for PTSD symptom monitoring 
(Ruglass et al., 2017).  
                The LEC, CAPS and MPSS-SR were utilized during baseline assessment. The CAPS 
was utilized at the end of the 12-week intervention period and subsequent follow-up assessments 
for those randomized to COPE and RPT. The MPSS-SR was used by participants across all 
groups to provide a weekly self-assessment of PTSD symptoms at baseline, randomization and at 
each of the scheduled COPE, RPT intervention or AMCG session including the post-intervention 
assessment. Administration of the MPSS-SR and CAPS also occurred at follow-up sessions for 







              Addiction Severity Index-Lite (ASI-Lite) is an abbreviated version of the Addiction 
Severity Index-5 that includes the most essential elements in a form that is reliable and valid as a 
composite measure of the severity of recent problems (McLellan, Caccioloa, Alterman, Rikoon, 
& Carise, 2006, p. 17).  The ASI-Lite was used to gather information regarding alcohol and 
substance use within the past thirty days and was administered at baseline, post-treatment, and 
follow-up assessments. The scores from the ASI-Lite were used to balance groups during 
randomization.  The Substance Use Inventory (SUI) was administered to gather and record 
frequency, quantity, context and consequences of alcohol and drug use. The SUI (Weiss, 
Hufford, & Navajits, 1995) was administered weekly to collect self-reported days of primary 
substance use during the seven days prior. This study provided the opportunity to examine 
whether attendance class membership might be predictive of substance use outcomes as 
measured by the SUI.  
Co-occurring Psychopathology 
            Clinical assessors utilized the Structured Clinical Interview for DSM-IV (SCID) to 
identify the presence of a co-occurring diagnosis of an Anxiety disorder, Major Depressive 
Disorder, or Dysthymia (renamed Persistent Depressive Disorder in DSM-5) and symptom 
severity. Lobbestael, Leurgans, & Arntz (2010) found moderate to excellent inter-rater reliability 
for the twelve Axis I disorders of SCID I (DSM-IV) in a mixed sample of n=151 inpatients, 
outpatients, and non-patient controls.  
           The Brief Symptom Inventory (BSI) is a 53-item-self-report instrument designed to assess 
psychological symptoms during the past seven days (Derogatis, 1993). The BSI has high 





dimensions, with two symptom dimensions utilized in the present study, Depression and 
Anxiety. The dimensions provide data regarding specific symptoms experienced in addition to 
symptom intensity using a 5-point Likert scale. Scores are reported using standardized area T-
scores.  
           The Difficulties in Emotion Regulation Scale (DERS) is a 41-item self-report measure 
with high internal consistency, good test-retest reliability (r=.88), high internal consistency (α = 
.93); and adequate construct and predictive validity (Gratz & Roemer, 2004). The DERS was 
administered on five occasions: at baseline; immediately following the 12- week intervention; 
and at one, two, and three months post-treatment. 
Data Analytic Approach 
            Data for participants (N=82) was entered using the data analytic software MPlus 
version 7.4. Latent Class Growth Analysis (LCGA) was used to account for heterogeneity and 
sub-groupings within the larger sample (Jung & Wickrama, 2008; Collins & Lanza, 2009). 
Latent class growth analysis, as a person-centered data analytic approach that focuses on the 
relationships among individuals, accomplishes the goal of classifying distinct subgroupings 
based on individual response patterns (Jung & Wickrama, 2008, p. 303).  Attendance across 
twelve time points (twelve sessions) was the binary outcome variable with attendance patterns as 
the latent class. While there are no specific class size requirements for latent class growth 
analysis with high entropy delineating models that closely fit the data, it is possible that with 
larger sample sizes, more classes may be identified (Curran, Obeidat, & Losardo, 2010). To 
facilitate increased accuracy in the identification of the best fitting model, entropy is utilized in 
conjunction with other criteria. Bayesian Information Criterion (BIC) provides a way to measure 





observations. MPlus reports the relative entropy or a rescaled version of entropy to convey the 
degree of certainty of classification. Thus, Bayesian information criterion (BIC) and entropy 
were considered together for the determination of the best-fitting model for the attendance of 
participants with PTSD-SUD randomized to active treatment. Class-specific response 
probabilities are parameterized using logit equations, as is typical of logistical regression 
analysis. Consequently, latent class model parameters can also be tested using Wald tests and 
Wald-based power analyses (Gudicha, Tekle & Vermunt, 2016, p. 32). 
The current study employed an analytic method developed by Fournier (Fournier et al., 
2009), which allows for the test of a range of potential predictors across construct domains while 
maintaining sufficient power (Zandberg et al., 2016, p.2). The Fournier approach was used to 
examine whether a number of demographic and diagnostic variables were predictive of 
attendance class membership and does so by grouping possible predictors or moderators within 
relevant domains. Given that this approach allows for the identification of variables that are 
predictive over other variables of interest within their domain, Type I error is minimized. In 
addition, Type II error is minimized in this approach because the analysis does not use all 
possible predictors in a single large model (Zandberg et al., 2016, p.4). In this study, the Fournier 
approach was used to identify baseline predictors of attendance via analyzing possible predictors 
within four primary domains of interest: demographic data, trauma variables; substance use 
(alcohol dependence; substance dependence; days of primary substance use); and additional co-
occurring psychopathology. Analyses were conducted using stepwise logistic regression. 
In step 1, all potential predictors of attendance pattern within a domain were entered in the 





non-significant predictors and then at the  p=.05 level allows for the variables significant at this 
level within given domains to be into the final model.  
Within the demographics domain, the variables analyzed were: age, years of education, 
sex, employment status, marital status, and race/ethnicity.  Given the nature and size of the 
sample as well as power constraints, racial identification for the analysis was classified as person 
of color or white, with the first category including individuals who identified as Hispanic/Latinx, 
bi-racial, multi-racial or other. The creation of a dichotomous variable in this manner may result 
in the failure to detect important differences pertaining to specific racial and ethnic groups and 
limits the interpretability of results on this demographic dimension (See Chapter 5 for further 
elaboration).   
The trauma/posttraumatic stress variables that were analyzed included continuous 
variables: severity scores by PTSD symptom cluster: re-experiencing/intrusion; avoidance; 
arousal; negative alterations of cognition/mood as well as by dichotomous variables such as: 
childhood trauma (yes/no), multiple traumas meeting DSMIV-TR criteria (yes/no), trauma type: 
physical assault (yes/no) and sexual assault (yes/no). The primary type of substance misuse (e.g. 
alcohol, substance) and the frequency of this use (e.g. number of days the primary substance was 
used in the past 7 days) were examined as potential predictors of attendance class membership. 
In addition, continuous and dichotomous variables related to other psychopathology that is 
frequently identified among those with PTSD-SUD were also examined for possible predictive 
relationships to attendance class membership. The baseline participant-characteristics examined 
included continuous variables, such as emotion dysregulation (total score on the Difficulties in 





self-report (BSI), as well as dichotomous variables related to a current MDD diagnosis (yes/no) 
or Anxiety diagnosis (yes/no) according to the baseline clinician-administration of the SCID.  
The associations between baseline diagnostic and demographic subject-specific variables 
and attendance class membership were analyzed using the Likelihood ratio Chi-squared test, a 
variant of Pearson’s Chi-Squared test. The test was used to compare observed and expected 
frequencies (under the given model) and determine whether the actual data point was equal to an 
expected outcome. For validity purposes, the test is well-suited to a larger sample size with a 
limited number of variables. The log-likelihood function is a function of the observed data points 
for all participants and the model parameters.  
The variables that were determined to have statistically significant relationships with 
attendance class were entered into the final regression model, while non-significant variables 
were excluded to minimize Type II error and create a more parsimonious model. Multi-linear 
regression within Latent Class Growth Analysis was used to evaluate associations between the 
attendance patterns and treatment outcomes. The study then assessed whether attendance class 









CHAPTER 4: RESULTS 
Baseline Characteristics 
             Of the participants randomly assigned to receive COPE (n=39), thirty-four attended 
between one and twelve sessions. Five did not receive this intervention according to protocol, 
with four participants not attending any sessions following the Motivational 
Interviewing/Randomization session and one participant discontinued from treatment due to an 
adverse event determined to be unrelated to study participation. All 39 participants were included 
in the analysis.  
 Of those assigned to RPT (n=43), four did not receive the intervention as randomized 
(did not attend any sessions) with 39 participants attending at least one RPT session. Twenty 
participants completed 1-week follow-up, twenty-nine completed 1-month-follow-up, twenty-
five completed 2-month follow-up, with twenty-three completing 3-month follow-up. All 43 
participants were included in the analysis. The baseline characteristics of 82 randomized 







Table 1. Demographic and Clinical Characteristics at Baseline  
 Characteristic COPE (n=39) RPT (n=43) 
  Demographic   Age, years 43.08±10.00 44.21±9.05 
                           Female 11 (28.2) 16 (37.2) 
Race/ethnicity    Black/African American 21 (53.8) 28 (65.1) 
       Hispanic/Latino 10 (25.6) 9 (20.9) 
                           White 6 (15.4) 6 (14.0) 
                           Other 2 (5.1) 0 
 Employment Pattern (past 3 yrs)  Full-time                                                      14 (35.9) 8 (18.6) 
                           Part time/student 15 (38.5) 18 (41.9) 
                           Unemployment/disability 10 (25.6) 17 (39.5) 
Education          Years completed 13.31±1.92 13.13±2.46 
 Crit. A Trauma Exposure   Physical assault 22 (56.4) 28 (65.1) 
                           Sexual assault  17 (43.6) 17 (39.5) 
                           Accident or disaster  1 (2.6) 5 (11.6) 
                           Sudden injury/death of other 12 (30.8) 20 (46.5) 
                           Other  6 (15.4) 0 
Multiple trauma  21 (53.8) 35 (81.4) 
Age at first trauma  17.90±13.64 18.49 ± 14.13 
Time since last trauma, years 16.15 ± 4.98 11.95±10.73 
Type of Use      Alcohol dependence 30 (76.9) 35 (81.4) 
                         Substance dependence  25 (64.1) 30 (69.8) 
                         Alcohol & substance dep. 16 (41.0) 24 (55.8) 
 Primary substance Alcohol  19 (48.7) 18 (41.9) 
                          Cannabis  3 (7.7) 4 (9.3) 
                          Cocaine  6 (15.4) 6 (14.0) 
                          Alcohol and stimulants 8 (20.5) 13 (30.2) 
                         Other polysubstance 3 (7.7) 2 (4.6) 
Other diagnoses Major Depressive Disorder  13 (33.3) 16 (37.2) 
             Anxiety (panic, phobia, SAD, GAD) 13 (35.1) 16 (43.2) 






Within a sample of treatment-seeking individuals with PTSD-SUD, subjects were 
expected to demonstrate multiple patterns of treatment attendance. Latent class growth analysis 
in MPlus version 7 (Muthén &Muthén, 2000; Muthén &Muthén, 2000) tested the hypothesis that 
multiple patterns of attendance would better characterize the sample than a single pattern of 
treatment attendance. Attendance was operationalized as a binary variable at each of twelve time 
points. Model information criteria (i.e. Aikeke Information Criteria (AIC), Bayesian Information 
Criteria (BIC), Sample Size Adjusted BIC), entropy and the adjusted Lo-Mendel-Rubin 
likelihood ratio test, and parsimony were all considered in determining the best-fitting model.  
Table 2. Global Fit of Attendance Pattern Models 
  1 class   2 classes   3 classes 
AIC 1238.33  713.2   560.89 
BIC 1245.55  730.57  587.36 
SSA BIC 1236.09  708.49  552.67 
Entropy NA  0.98  0.98  
LMR Adj LRT NA  p < .001  p < .001 
Note: A 4-class model failed to converge.  
AIC=Aikeke Information Criteria; BIC=Bayesian Information Criteria 
SSA BIC=Sample-Size Adjusted Bayesian Information Criteria 
LMR Adj LRT=Lo-Mendell-Rubin Adjusted Likelihood Ratio Test 
 
A three-class LCGA was determined to be the model of best fit with the lowest information 
criteria, high entropy (.98) suggestive of strong class delineation] (Gudicha, Tekle, & Vermunt, 
2016), and a significant adjusted Lo-Mendel-Rubin likelihood ration test, p <.001. A four-class 
model failed to converge and the three-class model was superior to the one or two-class models. 
Posterior probabilities of the best fitting model were utilized to classify individual subject’s 









Three distinct attendance patterns were identified. Completers (n=30, 36.6%) had high 
probabilities of attending all twelve treatment sessions (M=11.47, SD=0.82, range=10-12), 
whereas Titrators (n=26, 31.7%) demonstrated high probabilities of attending through session 
four and lower probabilities of attending subsequently (M=6.5, SD=1.63, range= 4-9). Droppers 
(n=26, 31.7%) had a high probability of dropout within the first few weeks of treatment 
(M=0.92, SD=1.02; range=0-3). 
Hypothesis 1A 
If multiple attendance patterns were identified, these patterns were expected to be 
associated with diagnostic variables including: severity of substance use, number of trauma 
exposures, childhood exposure to trauma, and the presence of additional co-occurring disorders 
characterized by emotional dysregulation (e.g. M.D.D.); and possibly associated with markers of 
socio-economic status (i.e. education, employment).  
Figure 1. The Three-Class Model of Best Fit  
 










No demographic variables were statistically significant predictors of attendance class type. 
The demographic variables analyzed were: age χ2(2, N=82)=3.21, p=.20, education χ2(2, 
N=82)=.58, p=.75, sex χ2(2, N=82)=.83, p=.66, employment status χ2(2, N=82)=1.42, p=.49, 
marital status χ2(2, N=82)=1.91, p=.39, and race/ethnicity χ 2(2, N=82)=2.52, p=.88.  
Trauma Variables 
Baseline assessments of trauma offered multiple ways to describe participants’ exposure 
and symptomatology: PTSD symptom severity by diagnostic cluster; trauma type (physical vs. 
sexual); number of traumas (utilizing the definition of trauma as an event that meets criterion A 
of the PTSD DSMIV-TR diagnosis); childhood trauma exposure vs. trauma exposure in 
adulthood only). An initial analysis was conducted setting the significance level at .15 to 
determine which symptoms might be worthy of closer analysis, with subsequent analysis of high 
hyperarousal symptom severity and multiple- criterion A traumas needed. After other trauma 
variables were removed and an analysis with a .1 significance level was conducted, high 
hyperarousal symptoms were determined to not reach significance, however, having experienced 
multiple-criterion A traumas at baseline was significantly associated with attendance 
membership class when tested at the .1 and .05 levels. Specifically, titrators were statistically 
more likely to have experienced multiple criterion-A level traumas compared to the droppers, b= 













Table 3  
Baseline Trauma Variables as Predictors of Attendance Class 
      χ2           Sig 
Re-experiencing/Intrusion   0.58 a .75
 a 
Avoidance 1.06 a .59 a 
Arousal 4.20 b .12b 
Negative Alterations 3.49 a .18 a 
Physical Assault 2.31 a .32 a 
Sexual Assault 2.78 a .25 a 
Multiple Traumas 6.04 c .049c 
Child Trauma 0.84 a .66 a 
Notes. Measurement taken at the baseline assessment. The CAPS provided 
symptom cluster scores. Childhood Trauma denotes trauma exposure 
(according to criterion A in DSM IV-TR) prior to 18 years.  
a Initial analysis conducted at p=.15 level 
b Analysis conducted at p=.1 level with one other variable 
c Analysis conducted at p=..05 level as single variable 
 
Substance Use Variables 
      Baseline assessments of substance use allowed for an analysis of possible relationships 
between attendance class-membership and substance-related variables. Among a sample of those 
already meeting criteria for SUD, the type or frequency of use was not significantly associated 
with attendance class membership. Specifically, there were no significant associations between 
type of dependence at baseline and attendance class: current alcohol dependence at baseline did 
not predict attendance class membership χ2 (2, N=82) =1.70, p=.43, nor did current substance 
dependence χ2 (2, N=82) = 2.63, p=.27. There was also no significant relationship between the 
number of days the primary substance was used in the 30 days prior to baseline and attendance 





Other Psychopathology Variables 
            Baseline assessments provided the opportunity to determine if psychopathology other 
than PTSD and SUD, specifically current Major Depressive Disorder (MDD); diagnosis of an 
anxiety disorder; emotion dysregulation; anxiety severity (BSI dimension); and depression 
severity (BSI dimension); were associated with attendance group class. The presence of a current 
MDD diagnosis was associated with class membership as noted in Table 4. Specifically, titrators 
were significantly more likely to have a current MDD diagnosis than completers, b= -1.76, Wald 
χ2 (1) =7.88, p<.01. No other indicator of co-occurring psychopathology or psychopathology 
severity was found to be significantly associated with attendance class.  
 
Table 4  
Other Psychopathology Variables as Predictors of Attendance Class 
      χ2           Sig 
Emotion Dysregulation   0.51 a .77
 a 
Depression Self-Report  0.61 a .74 a 
Anxiety Self-Report 3.31 b .19b 
Current MDD Diagnosis 8.98c .01c 
Current Anxiety Diagnosis 2.31 a .17 a 
Notes. The Emotion Dysregulation variable is the Difficulties in 
Emotion Regulation Scale (DERS) Total Score. Depression and Anxiety 
Self-Report scores were scale scores from the Brief Symptom Inventory. 
Current MDD (Major Depressive Disorder) and Anxiety diagnoses were 
drawn from the clinician-administered SCID.  
a Initial analysis conducted at p=.15 level  
b Analysis conducted at p=.1 level with one other variable 
c Analysis conducted at p=.05level as single variable 
  
  In the final model, multiple trauma χ2= 6.17, p=.04, and co-occurring current MDD 





were less likely to have experienced multiple trauma relative to titrators, OR=0.19, 95% CI 
[0.05, 0.74], p=.02, and completers were less likely to have comorbid depression relative to 
titrators, OR=0.15, 95% CI [0.04, 0.55], p=.004. See the final model including all significant 
variables predictive of attendance class in Table 5. 
Table 5  
Final Model: Baseline Predictors of Attendance Class Membership 
      χ2           Sig 
Multiple Traumas 6.17 .04 
Current MDD 9.56 .01 
Note. Significant at the p<0.05 level.  
MDD=Major Depressive Disorder 
Hypothesis 1 B 
If different attendance classes were identified among a treatment-seeking sample of 
participants with PTSD-SUD, it was expected that the dropout, titration, and completion rates for 
those randomized to RPT would differ from those randomized to COPE. More engagement vis-
à-vis titration was hypothesized for the COPE group. No significant results were found for 
Hypothesis 1B. Though different attendance classes were identified, there were no significant 
differences in the distribution of attendance patterns according to treatment type. The distribution 
of participants following each attendance pattern was not significantly different between 











Table 6  
Distribution of attendance patterns according to treatment type  
   Completers      Titrators  Droppers 
Treatment              
COPE N 13a  11a  15a 
          % within treatment 33.3%  28.2%  38.5% 
           % within pattern 43.3%  42.3%  57.7% 
RPT    N 17a   15a   11a 
 % within treatment 39.5%  34.9%  25.6% 
 % within pattern 56.7%  57.7%  42.3% 
Notes: COPE=participants were randomly assigned to a 12-week intervention of 
Concurrent treatment of PTSD and substance use disorders using prolonged exposure 
(COPE); RPT= participants were randomly assigned to a 12-week intervention of 
Relapse Prevention Therapy (RPT). 
a Pattern categories do not differ significantly from each other at the .05 level. 
 
Hypothesis 2 
Membership to a particular attendance class was expected to have an effect on outcome 
measures of post-traumatic stress, substance use and global psychiatric functioning. This 
hypothesis was tested using a mixed-effects model with attendance class membership as the 
independent variable and the Post-traumatic Stress Symptom-Self Report (MPSS-SR), Clinician 
Administered PTSD Scale (CAPS) and Substance Use Inventory (SUI) as outcome variables. 
Given the data that was absent for the droppers from sessions that were not attended, it was not 
possible to make meaningful interpretations regarding symptom changes for this attendance class 
during the initial treatment period or post-treatment. Interpretations are more possible for 





Titrators and completers are not distinguishable from each other in terms of attendance 
from baseline assessment through the fourth session, with attendance diverging at this juncture 
for session five with titrators then becoming significantly less likely to attend each subsequent 
session in contrast with completers. At baseline, titrators and completers are not significantly 
distinguishable from each other on measures of PTSD symptom severity (MPSS-SR) though a 
significantly higher proportion of titrators experienced a multiple criterion-A traumas relative to 
completers. Data from Baseline through session 4, indicate that titrators report a more rapid 
decline in post-traumatic symptom severity vis-à-vis completers as evidenced by a significant 

















Figure 2. PTSD Symptoms in the Initial Treatment Phase  
BL = Baseline Assessment, MI=Motivational Interviewing session/Randomization S1= 







The non-significant differences between completers and titrators on self-reported PTSD 
symptoms seen prior to the initiation of treatment proper (e.g. the divergence between BL and 
S1) appears to be due in part to a placebo effect.  Recent fMRI research of placebo in a clinical 
trial for chronic pain suggests that there may be greater activity in the middle frontal gyrus brain 
region during a placebo effect, suggesting that increased attention and emotional support directed 
toward the self may have healing effects (Tétreault, Vachon-Presseau, Schnitzer, Apkarian, & 
Baliki (2016). Prior treatment history may influence expectancy of treatment benefits suggesting 
potential value in controlling for this variable.  
Analyzing this same initial treatment period in relation to substance use, titrators and 
completers were not significantly different from each other in mean days of primary substance 
(SUI). Completers and Titrators show a similar decline from a mean of around four use days of 









          Figure 3. Mean Days of Use of the Primary Substance for the Prior 7 Day Period 
BL = Baseline Assessment, MI=Motivational Interviewing session/Randomization                         
S1= Treatment Session 1 with subsequent sessions numbered accordingly 
Following an analysis of the initial treatment response, post-treatment data was analyzed though 
findings were inconclusive given the lack of sufficient sample size to accurately determine an 
effect for these time points. Notwithstanding, the data gathered post-treatment reveals a possible 
avenue for further investigation as the mean PTSD scores on the CAPS were lower for 
completers who attended follow-up sessions relative to the titrators who attended follow-up 
sessions at all post-treatment assessments at one-month, two-month and three-months subsequent 
to active treatment. Post-treatment data showing use days of the primary substance was non-
interpretable, with no indicated trend for exploration across the one-month, two-month and three-






CHAPTER 5: DISCUSSION 
Irregular treatment attendance has been a noted concern in the PSTD-SUD literature 
(Brady et al., 1994). Treatment seekers with PTSD-SUD are expected to have poor rates of 
treatment attendance with vulnerability to disengagement from the therapies that have been 
shown to facilitate considerable relief and recovery (Pineles et al., 2011). Recent literature has 
demonstrated that for some patients with PTSD-SUD, attending treatment sessions 50-80% of 
the time is associated with equal or greater outcomes when compared to participants attending all 
sessions within the same study (Hien et al., 2012). The nuances of the treatment dose-response 
relationship and its variability will benefit from on-going research to elucidate meaningful 
subsets of those with full or subthreshold PTSD-SUD (Hien et al., 2015). Treatments for the 
complex co-occurring problems of those with PTSD-SUD utilize approaches that demand 
differing levels of cognitive, affective, and bodily engagement (Courtois & Ford, 2009); the 
expectations and realities of treatment vary, with both exerting influence on the way patients 
engage in treatment initially and attend (ir)regularly over time.  
Few studies have examined whether patients with PTSD-SUD attend treatment in 
predictably different ways when randomly assigned to a treatment with prolonged exposure 
(COPE) or a cognitive behavioral therapy focused on substance dependence without direct 
engagement of the trauma (e.g. Relapse Prevention Therapy). The present study elucidates the 
ways a subject’s diagnostic complexity at baseline may be predictive of attendance patterns and 
irregularities. This person-centered study illustrates that within a population of those with PTSD-
SUD, co-occurring diagnoses of depression and the multiplicity of trauma exposures experienced 
relate to the ways individuals drop out, titrate or complete a prescribed course of psychotherapy. 





treatment that addresses trauma directly may experience significant decreases in symptoms with 
far less than perfect attendance (e.g., Kaysen et al., 2014; Hien et al., 2012; Mills et al., 2016). A 
more detailed examination of study findings will be presented in the following section 
contextualized by the subsequent discussion of limitations and future directions for research. 
Finally, clinical implications and conclusions will be discussed.  
Summary of Findings 
 Like the sample used in a treatment effectiveness study of Seeking Safety (Hien et al., 
2012), the heterogeneity of the current group of treatment seekers with PTSD-SUD was 
effectively characterized by demarcations according to attendance data. Though the clustering of 
participants in this dissertation study looked somewhat different from the all-female sample 
using a present-focused therapy for PTSD-SUD in a group format, the samples from Hien and 
colleagues (2012) and the current study (Ruglass et al., 2017) are both aptly described by three 
class models, showing distinct classes of participants who interact with service delivery by 1) 
dropping out of treatment early, 2) titrating treatment with declining probabilities of attendance 
in later sessions, or 3) attending all or almost all intervention opportunities as treatment 
completers.  
Demographic variables were not predictive of treatment attendance patterns in the current 
dissertation research. Psychotherapy research in applied mental health settings (Defife, 2010) 
and within epidemiological research literature (Edlund et al., 2002) found low socio-economic-
status as the most consistent predictor of treatment attrition (e.g. years of formal education, 
employment, financial stability) though some research qualifies this as a more robust predictor in 
the early phase of treatment (Barret et al., 2008). Despite this trend, variables that are markers of 





predictive of attrition in controlled trials or in studies with a more restricted range. Overall, the 
majority of the participants in the present study had limited financial means and low socio-
economic status. Consequently, the limited diversity within this sample in terms of SES-related 
variables (e.g. employment status, years of education) made it unlikely that these variables could 
be predictive of attendance class membership in this particular study. Those with PTSD-SUD 
and high SES are unlikely to seek treatment in a clinical research study involving randomization. 
While there have been some exceptions, most PTSD psychotherapy research has not found 
demographic differences between those who drop out and complete treatments (van Minnen et 
al., 2002), however differences among operationalized definitions of attendance-related 
terminology (Najavits & Hien, 2013) and methodological limitations could obfuscate possible de 
facto demographic predictors. While no attendance differences were found according to race or 
ethnicity in this sample, the groupings of patients according to person of color vs. white may be 
considered problematic given the limited number of White participants (n=12).  Black/African 
American (n=49) as the comparison group would have greater capacity for interpretability. 
While the White comparison group was selected due to failure of specification by this writer and 
become the default choice of the supporting statistician, this occurrence despite representing 
such a small subsample, reflects the pervasive and insidious nature of racism where white 
participants have assumed a privileged visibility in research studies. This writer managed the 
choice through the rationalization that the racial and class divides impacting participants were 
such that people of color more so than whites could have experienced heightened vulnerability to 
treatment barriers given the realities of a country which continues to legalize hegemony. This 
rationalization, however, is questionable and contradicts the recommendations of Burlew, 





minorities to a non-Hispanic White sample may not only ignore important group differences 
among various ethnic minority groups, but may also lead to erroneous conclusions about 
treatment responsiveness and treatment effects.  
Although there were no demographic variables that were predictive of attendance class 
membership, there were clinical variables that did predict how participants attended treatment 
sessions. Recently, Cui et al. (2016) found few variables to be significantly predictive of 
treatment attendance, and hypothesized that this might be attributable to the complexity of co-
occurring disorders. Mills and colleagues (2016) noted the possibility that a lack of predictors of 
treatment outcomes may be related to small sample size, though this was also used as an 
argument for the wide applicability of COPE.  Consistent with Cui et al. (2016), the current 
study (N=82) identified only two variables that were predictive of treatment attendance. 
Specifically, the presence of current co-occurring Major Depressive Disorder and the number of 
traumatic exposures were predictive of attendance class membership, facilitating differentiation 
among droppers, titrators and completers.  
Subjects classified as titrators (according to the model of best fit) could not be 
distinguished from completers in terms of attendance differences until the fourth session, after 
which point titrators had lower probabilities of attending the remaining sessions. The attendance 
patterns of the participants classified as droppers, titrators, and completers can be distinguished 
from each other not only by attendance patterns, but also by baseline-characteristics. Current 
MDD diagnosis was predictive of attendance pattern; titrators were more likely to have current 
MDD than completers. Again, this is consistent with the literature on patients with SUD and co-
occurring disorders which found a positive correlation between additional co-occurring 





occurring diagnoses often suggest a more difficult treatment course, current MDD was not the 
only additional co-occurring disorder (see Table 1), suggesting that those with MDD-PTSD-SUD 
experienced a unique relationship among symptoms, treatment, response, and attendance. The 
thoughts (e.g. negativistic perspective, concentration difficulties, suicidal ideation), emotions 
(e.g. hopelessness, sadness, guilt), and behaviors (e.g. social isolation, withdrawal, changes in 
sleep and energy level) associated with MDD may make it more challenging for participants to 
both to decide to attend each therapy sessions and execute this decision. Those who titrated 
treatment reported a more rapid initial decline in trauma symptoms, which may have driven 
reduced attendance subsequently. Perhaps some titrators who began to attend fewer sessions 
were less optimistic about the effects of further treatment. Some titrators may also have been 
attempting to manage emotion (dys)regulation through attending fewer sessions. Titrators had 
decreased probabilities of attending later sessions in a Seeking Safety study (Hien et al., 2012) as 
they did in this COPE study, however, the earlier titration process begun in the study of COPE 
may point to a link between perceived tolerability, titration, and the use of in vivo and imaginal 
exposures, though there are other potentially confounding differences, such as group modality 
and present vs. past-focused treatment.  
Titrators in the present study were more likely to have been exposed to multiple traumas 
compared to those subjects who were droppers, the participants who left treatment early in the 
protocol and attended the fewest overall sessions. Subjectively, droppers may have experienced 
less need for treatment vis-à-vis titrators and completers, perhaps due to more limited impact of 
trauma exposure on the life course. In the context of the GEL model, which posits that patients 
tend to leave treatment when a patient’s improvement has reached a good enough level 





Baseline Assessment, Motivational Interviewing and initial session(s), whereas titrators may 
have achieved sufficient relief following sessions four through nine. Alternatively, it is also 
possible that droppers had the most difficulty with the development of the therapeutic alliance, a 
factor interfering with motivation to attend and openness to the varied elements of the offered 
treatment. 
Studies have shown that treatment completers with PTSD-SUD demonstrated greater 
levels of impairment when compared to non-completers, variably defined (Brady et al., 2001; 
Najavits et al., 1998; Hien et al., 2012). While completers may have exhibited higher levels of 
motivation regardless, this finding also suggests that those who complete treatment may also be 
compelled to do so by subjective experiences of distress. 
There were no significant differences in the distribution of the three distinct attendance 
patterns across the two active treatment types. The lack of significant findings suggests that the 
use of an integrated PTSD-SUD treatment utilizing prolonged exposure (COPE) did not lead to 
higher rates of early dropout or greater numbers of titrators when compared to those randomized 
to Relapse Prevention Therapy (RPT). In a study of veterans with co-occurring PTSD-SUD-
MDD, Cui et al. (2016) found that the use of specific trauma-treatment for individuals with 
PTSD-SUD-MDD did not result in higher rates of dropout as compared to treatment that did not 
specifically address the trauma. A notable methodological difference, however, was the use of a 
two-phase treatment approach with all veterans first enrolled in 12 weeks of integrated cognitive 
behavioral therapy for depression and substance use delivered in a group prior to receiving either 
12 weeks of individual CBT or 12 weeks of individual Cognitive Processing Therapy modified 
to address co-occurring PTSD-SUD (Cue et al., 2016). Cui et al. (2016) and the current 





found fewer participants completed trauma-focused treatment than treatment as usual (although 
given greater positive effects with use of trauma-specific interventions for PTSD-SUD, these 
therapies were still recommended as the most effective option).  
Given the size of this dissertation sample, a lack of significant findings for hypothesis 1B 
could also represent failure to detect a small difference in distribution of attendance class 
membership by treatment type. Cui et al. (2016) demonstrated individual, integrated trauma 
treatment as effective after a group treatment; the 12-week group process may have facilitated 
safety and stabilization for subsequent processing of traumatic memories (Herman, 1997) using a 
modification of Cognitive Processing Therapy (as opposed to PE). If failure to detect a 
difference in the distribution of attendance class patterns by treatment type occurred in this 
dissertation research, findings such as those of McDonagh and colleagues (2005) who found 
higher dropout (>40%) associated with PE as opposed to present-centered trauma treatment, 
would be buttressed. Consequently, caution regarding the interpretation of the lack of a 
significant difference in the distribution of attendance class membership across the two active 
treatments (COPE and RPT) is necessary.   
Though the sample was limited in terms of participant numbers, the racial and ethnic 
diversity of the sample with considerable heterogeneity in trauma exposure, substance use, 
motivation level and functioning does mirror the population found in many community SUD 
programs and mental health clinics (Ruglass et al., 2017). If the finding that COPE does not lead 
to higher rates of dropout and treatment titration compared to RPT or other SUD-only treatment 
can be further replicated, clinical providers and the treatment settings within which they operate 
may experience further incentive to employ integrated treatments with prolonged exposure and 





traumatic memories directly. Further replication would reduce possible misinterpretations of 
failure to detect significant differences, especially given the inherent complexities of working 
with a dually diagnosed population (Cui et al., 2016; Robert et al., 2014).  
In the initial treatment phase (Baseline – session 4), subjective post-traumatic stress 
symptom severity decreased more quickly for titrators than it did for completers, (a factor which 
may be driving the lower probabilities of attendance among titrators for later treatment sessions). 
There were no significant differences in substance use among completers and titrators within the 
initial treatment phase (Baseline – session 4). In an early randomized, controlled trial of COPE, 
Mills et al. (2012) suggested that decreases in substance-related symptomatology lagged behind 
decreases in trauma symptoms. Consequently, significant differences in substance use in the 
initial treatment phase by attendance class were not anticipated.  
The non-significant differences between completers and titrators on self-reported PTSD 
symptoms seen prior to the initiation of treatment proper (e.g. the divergence between BL and 
S1) may be explained by a placebo effect.  Recent fMRI research of placebo in a clinical trial for 
chronic pain suggests that there may be greater activity in the middle frontal gyrus brain region 
during a placebo effect, suggesting that increased attention and emotional support directed 
toward the self may have healing effects (Tétreault, Vachon-Presseau, Schnitzer, Apkarian, & 
Baliki (2016). Prior treatment history may influence expectancy of treatment benefits suggesting 
potential value in controlling for this variable.  
Attrition impacted the numbers of participants available for analysis of the relationship 
between attendance pattern and treatment outcomes at the end of the intervention period. There 
was insufficient power to detect associations between attendance class membership and 





month follow-up phase given both the difficulties recruiting a large sample initially (Ruglass et 
al., 2017) and the extent of attrition subsequently. For a more comprehensive explanation of 
methodological concerns related to secondary analyses see Hien et al. (2015). Though no 
conclusions can be drawn, collected data does indicate a possible trend for exploration: the mean 
PTSD severity scores of completers (generated by assessors blind to treatment type using the 
CAPS) are lower than the mean scores for titrators at one month, two months, and three months 
post-treatment. While this may be an artifact of selection bias, it is possible that those with more 
rapid initial decline in trauma responses begin to titrate treatment engagement via attendance 
when higher rates of attendance could help maintain symptom reduction over a longer period.  
In summary, measurement of co-occurring depression and trauma exposure at baseline 
predicts how individuals with PTSD-SUD attend treatment and thus warrants increased attention 
in the therapeutic relationship and larger service delivery systems. 
The relationship between attendance class and treatment outcomes can be situated in the 
context of the main outcome paper analyzing participants (N=110) randomized to COPE, RPT, 
and the Active Monitoring Control Group (AMCG) (Ruglass et al., 2017). The AMCG group 
differed from the two treatment groups [lower CAPS scores relative to each treatment groups; 
significantly lower proportion of individuals with current MDD compared to RPT and COPE]. A 
difference in the numbers of sessions attended among COPE, RPT, and AMCG was found, and 
was attributable to the difference between COPE and AMCG specifically. However, the number 
of sessions attended was not a significant covariate when included in the outcomes model for the 
original analyses (Ruglass et al., 2017, p.6). In contrast, Mills and colleagues (2016) found the 
number of COPE sessions attended significantly predicted change in PTSD symptom severity in 





alongside Ruglass et al. (2017) the predictive relationship of sessions attended with PTSD 
symptom severity in Mills and colleagues (2016) might be related to differing attributes of the 
sample and the function of these differences as moderator variables. Bias related to detection or 
attrition in either sample may also help explain the difference in findings.       
Limitations and Future Directions for Research 
As the original study was not designed to compare intervention lengths, attendance 
patterns were participant-driven. Utilizing prescribed treatment dosages (Jacquart et al., in press) 
would have afforded greater understanding of the nature of the treatment dose-response 
relationship as well as the possible influence of subject-expectancy effects of prescribed 
treatment dosage on attendance. Future studies that manipulate treatment dose may provide 
additional data regarding treatment-dose-response and attendance-related variables. In future 
research on COPE, specific dose manipulation of the imaginal exposure sessions may be 
particularly useful for improved patient-treatment matching. Imaginal exposures of shorter 
duration (20 minutes of a 60 minute session) have already been shown to be equally effective to 
those of longer duration (40 minutes of a 90 minute session) (Nacasch et al., 2015). 
The limited sample size of the present study impeded the examination of attendance 
pattern on outcomes at one, two, and three months post-treatment. Reduced attendance during 
the follow-up period in addition to selection bias makes the data from this phase beneficial for 
hypothesis generation more than hypothesis testing. Cloitre, Petkova, Su, & Weiss (2016), found 
the combination of symptom burden and patient strengths to be predictive of differential 
responses to PTSD treatments that were skills-based, exposure-based, or provide both types of 
intervention.  While replication is needed for those with PTSD and those with PTSD-SUD, 





receiving skills and exposure, least well in an exposure-only group and moderately well when 
receiving a skills-only treatment, specifically Skills Training in Affect and Interpersonal 
Regulation (STAIR) (Cloitre et al., 2016). The sample used does not reflect the full heterogeneity 
of the current sample with PTSD-SUD, but provides evidence that differential responses based 
on identification of meaningful moderators may become apparent only in follow-up rather than 
immediately post-treatment. The impact of sample size on power to detect an effect in the 
follow-up period suggests challenges in the identification of the most vulnerable to deterioration 
across and within treatments. The approach of Cloitre and colleagues (2016) of identifying 
combined moderators that also incorporate strengths points to useful methodological approaches 
for future research related to the identifications of clinically meaningful patient subgroups, 
differential treatment effects and precision medicine.   
The study of interaction effects in this dissertation research was also impacted by sample 
size. For example, it was not possible within the current study to examine the extent to which 
participants with multiple traumas and current MDD had superior trauma-related outcomes when 
they titrated their response to COPE as opposed to completed COPE or whether titration was a 
more effective strategy for those with MDD when randomized to COPE as opposed to RPT. 
Furthermore, the scant outcome data available for droppers limited this study in its ability to 
capture the full scope of the relationship between treatment attendance and outcomes.  
An additional limitation of the study was the failure to include participant’s alteration of a 
particular treatment dose via the full range of attendance irregularities, specifically late arrivals 
or early departures from sessions.  
The present study indicates that those who would go on to be classified as titrators, but 





steeper initial decline in PTSD symptoms on a self-report measure. Additional study would be 
required to understand the extent to which symptom relief and intra-subjective comparison of 
current relief to the “good enough level” may have contributed to the subsequent decreased 
likelihood of attending subsequent sessions. Those who titrated treatment seem to have 
experienced some relief in terms of trauma symptoms on the self-report measure; however, some 
of those who dropped out or titrated treatment may have left treatment due to the expectation that 
either treatment or further treatment would not be helpful or would become less tolerable.  
A clinician-assessment of participants’ trauma symptoms at session 3 or 4 could have 
provided a valuable comparison to the self-report data. For those receiving COPE, in vivo 
exposure begins in session four and imaginal exposure begins in session five. Were there some 
participants who were responding to the pace of the treatment and uncertainty regarding repeated 
retelling of personal trauma? Tapping into the (un)conscious participant rationale for reduced 
attendance could provide useful evidence regarding whether expectations for and experiences of 
exposure interventions may be a partial contributor to attendance titration. Were there different 
explanations for titration among RPT recipients? The extent to which unique factors related to 
treatment type (e.g. imaginal exposure) contribute to titration for particular subsets of individuals 
seeking help for PTSD-SUD requires further examination.  
Further study may be useful in understanding the extent to which patients’ formulation of 
an individual “good enough level” is impacted by an initial or evolving understanding of 
treatment type. If the relationship between initial symptom relief, attendance and outcomes was 
clarified for sub-groupings of participants and this data was shared or discussed thoughtfully 
with participants themselves, would attendance patterns be impacted? If so, would that be helpful 





counter-productive? Can we understand a titrated experience of treatment differently if for some 
patients “less is more”? If therapeutic work is happening in between sessions or continues to be 
experienced even after a protocol is finished (Symington, 2012), does this change the view of 
treatment titration? Are there ways to deliver flexible treatment that are respectful of the 
limitations of human and financial resources? This study engenders more questions than 
answers, some of which may be resolved through studying the influence of other variables on 
treatment attendance.  
The literature indicates that additional variables, not measured directly in the present 
study, may be predictive of attendance pattern including social support (perhaps partially 
captured in the present study by demographic variables related to marriage and employment); 
therapeutic alliance; motivation; and past treatment history (Mills et al., 2016). Psychotherapy 
researchers have established the important role of therapeutic alliance, training, perceived 
empathy of clinician as well as other factors, such as social support, which have direct influence 
on an individual’s likelihood of making effective use of a therapeutic relationship in terms of 
attendance and outcomes. Specifically, “therapeutic alliance has been associated with better 
treatment engagement, better adherence, and less dropout across various treatments and 
disorders” (Keller, Zoellner, & Feeny, 2010, p. 974). Though the quality of therapeutic alliance 
is seen to impact treatment effectiveness across diverse types of therapies and therapists, 
evidence of the predictive capacity of alliance on outcome may vary by psychiatric disorder 
(Sawaya, 2013, p.18) with early alliance measurement as a more powerful predictor than later 
alliance measurement (Barber, Connelly, Crits-Cristoph, Gladis & Siqueland, 2000; Sawaya, 
2013). In a comparison of ten weeks of Prolonged Exposure to ten weeks of medication 





[Working Alliance Inventory] was associated with PE adherence (r=.32, p .05) and overall 
treatment completion (r=.19, p .05)” (p. 974) with trauma-related social support predicting early 
alliance strength. A measure of early therapeutic alliance may have been able to predict 
developing attendance patterns for titrators and completers, an experience that may guide 
clinicians to adjust their efforts to develop rapport and engage participants through more tailored 
means within the treatment.  
The present study did not identify differences in motivation at baseline. The class of 
treatment completers may capture participants who are both highly motivated in terms of 
attending any therapeutic services offered as well as implementing strategies from either therapy 
designed to promote recovery and reduce negative outcomes including substance or alcohol use. 
A subject’s readiness and confidence in the capacity to make change can be seen as indicative of 
self-efficacy, a construct that is consistently associated with improvement in alcohol-related 
outcomes (Williams, Horton, Samet, & Richard, 2007, p.432). Classifying participants’ 
motivation level prior to randomization may have identified a latent factor contributing to 
attendance patterns. However, there is at least some indication that motivation and its 
relationship to attendance may be complicated. Tate et al. (2011) did not find motivation to be 
related to treatment retention though differences between self-reported motivation and clinician-
assessed stage of change may be markedly different.  
Subsequent studies may benefit from the inclusion of a clinician-administered measure to 
assess baseline motivation prior to and following the randomization process, as this may be 
predictive of participant attendance in treatment and be responsive to type of treatment being 
received. Motivation for change may be captured by an assessment that operationalizes the 





Motivational Interviewing (Miller & Rollnick, 2002) such as the University Rhode Island 
Change Assessment Scale (URICA) (Pantalon et al., 2002). Audio recordings of the pre-
randomization Motivational Interviewing session could be used to code participants’ 
communications according to criteria indicative of: pre-contemplation, contemplation, 
preparation, action, or maintenance. In community samples, those in the precontemplation phase 
would be unlikely to seek treatment for PTSD, endorsing beliefs that they can handle difficulties 
on their own, outside of the traditional mental health framework (Koenen, Moffitt, Caspi, Taylor 
& Purcell, 2003). While participants in the present study came from the community in addition 
to those seeking mental and physical health services, monetary compensation for study 
participation may have resulted in higher rates of inclusion of those in the precontemplation 
phase, than may have occurred without compensation.  
The present study highlights the need for greater transparency with regard to treatment 
attendance data in treatment efficacy, effectiveness, and applied research. Clear and more 
consistent definitions of attendance-related terminology and classification are warranted. Mills 
and colleagues (2016) successfully communicated how many participants attended each COPE 
session (Figure 1); this transparent reporting practice may help researchers make cross-study 
comparisons with greater effectiveness. Future clinical research studies comparing treatments for 
those with PTSD-SUD will benefit from this methodology in the reporting of attendance data. 
Including data regarding the relative proportion of early vs. later dropouts, as well as the extent 
to which some dropouts may be better understood as titrators, may increase capacity for 
informed decision-making related to treatment-fit and service delivery. Furthermore, additional 
research with larger sample sizes is necessary to identify clinically meaningful subgroupings 





psychological care that is most effective (Hien et al., 2015; Lopez-Castro et al., 2015; Hien et al., 
2012). Building upon the current study, the link between symptom relief (and other meaningful 
measures of change that may be more difficult to quantify), treatment titration and post-treatment 
outcomes will benefit from further investigation, particularly in terms of understanding the 
“good enough dose” and its relationship to treatment-fit.  
Clinical Implications and Conclusions 
While evidence suggests that a large majority of individuals with PTSD-SUD greatly 
prefer to receive integrated treatment addressing trauma and substance related symptoms (Back, 
Brady, Jaanimagi, & Jackson, 2006; Brown et al., 1998), a substantial subset of these same 
participants may likely drop out of an integrated treatment addressing PTSD symptoms with 
Prolonged Exposure prior to the initiation of exposure procedures (McDonagh et al., 2005). 
Seventy-five percent of drop-outs in a preliminary study of COPE (differently named) left 
treatment prior to the use of in vivo or imaginal exposure (Brady et al., 2001), whereas within the 
current study 38.5% of those receiving COPE dropped out of treatment prior to utilization of in 
vivo or imaginal exposure techniques.  
 Early and on-going discussions with patients regarding desired symptom reduction and 
role functioning, as an informal assessment of patients’ formulation of “good enough” relief, can 
occur in the context of dialogue regarding patient’s expectations for intervention components 
(e.g. prolonged exposure).  Open discussion of patient concerns may help reduce attrition 
(Killeen, Back, & Brady, 2011) to respond to individual differences in the therapeutic window 
(Hien et al., 2009).  
Client-specific baseline variables of co-occurring depression and multiplicity of trauma 





attention during service provision for individuals with PTSD-SUD. Further studies that examine 
interaction effects between patient characteristics and treatment type with this population may 
allow for greater individualization in regards to treatment, making effective use of the 
identification of sub-groupings and their differential responses to therapeutic intervention 
(Project MATCH Research Group, 1997; Miller & Rose, 2009; Hien et al., 2012; Cloitre et al., 
2016; Mills, et al., 2016).  A clarified relationship between treatment attendance patterns and 
outcomes may offer support for treatment delivery models of increased flexibility. Participants 
with co-occurring PTSD and SUD who are motivated for recovery may be in the best position to 
determine when, how often, or which sessions to attend; such perspectives might not only be 
empowering to patients but might be efficacious as well. Understanding the ways patient-
characteristics of individuals with PTSD-SUD relate to treatment titration (via irregularities in 
attendance) has the potential to improve overall treatment engagement on an individual and 
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